Section |
Name |
Details |
10.01.03 |
Abatacept Orencia® |
Intravenous infusion 250mg vial
Injection 125mg pre-filled syringe |
02.09 |
Abciximab |
Injection - Restricted for stents only
|
08.03.04.02 |
Abiraterone Zytiga® |
|
04.10.01 |
Acamprosate Campral EC® |
Tablet 333mg
Usual dose range: Bodyweight OVER 60Kg 666mg TDS, Bodyweight UNDER 60Kg 666mg breakfast, 333mg midday and 333mg at night |
06.01.02.03 |
Acarbose Glucobay® |
Tablet50mg 100mg
Useful in the occasional overweight patient but limited by gastrointestinal intolerance
|
02.08.02 |
Acenocoumarol |
Tablet
Only used for those patients intolerant of warfarin and phenindione, or existing patients |
20 |
Acetarsol Suppositories |
FORM AND STRENGTH: Suppository 250mg
INDICATION: Drug resistant proctitis
DOSE: 250mg twice daily
PACK SIZE:
SUPPLIER: Cardinal Health Martindale
LICENSE TYPE: UK unlicensed specials manufacturer
PRESCRIBING CONSULTANT: Dr C Kenneth
DATE AUTHORISED: 16/03/2012 |
11.06 |
Acetazolamide Diamox® |
Tablets 250mg, Capsules MR 250mg |
11.08.02 |
Acetylcholine Chloride Miochol-E® |
|
03.07 |
Acetylcysteine |
|
11.08.01 |
Acetylcysteine |
|
18 |
Acetylcysteine Parvolex |
|
20 |
ACETYLCYSTEINE 10% PRESERVATIVE FREE |
FORM AND STRENGTH: 10% preservative free eye drops
INDICATION: Severe dry eyes
SUPPLIER: Moorfields Pharmaceuticals
PRESCRIBING CONSULTANT: Dr A Reynolds
DATE AUTHORISED: 26/07/2012 |
11.08.01 |
Acetylcysteine 5% with Hypromellose 0.35% Ilube® |
Eye drops |
20 |
ACETYLCYSTEINE granules |
FORM AND STRENGTH: Granules 1g, capsules 600mg
INDICATION: Idiopathic Pulmonary Fibrosis
SUPPLIER: IDIS
PRESCRIBING CONSULTANT: Dr B Jacobs
DATE AUTHORISED: Granules 20/12/2005, Capsules 13/06/2007 |
05.03.02.01 |
Aciclovir |
|
13.10.03 |
Aciclovir |
|
24.01 |
Aciclovir |
Indication:
Herpes zoster, treatment Varicella zoster, treatment
Dose:
20mg/kg every 8 hours
For further information see Y&H ODN formulary - Scroll to top
Administration:
Renal function
Further Info:
Maintain adequate hydration
Supply:
Available on NNU as a stock item. |
11.03.03 |
Aciclovir eye ointment Zovirax® |
Eye ointment 3% |
13.05.02 |
Acitretin Neotigason® |
Capsule 10mg, 25mg
Dermatology specialist only
|
20 |
Acitretin oral suspension |
FORM AND STRENGTH: 1mg/ml oral suspension
INDICATION: Harlequin Icthyosis
SUPPLIER: Novo labs 0116 2230099
PRESCRIBING CONSULTANT: Dr Heike Bauer (17/05/2007) and Dr Chris Day (20/01/2010)
|
03.01.02 |
Aclidinium Eklira Genuair® |
Inhalation powder inhaler (400 micrograms/dose) |
18 |
Activated charcoal |
|
06.01.01.01 |
Actrapid® Soluble insulin |
Short acting human soluble insulin
10mL vial
|
01.05.03 |
Adalimumab Amgevita |
Amgevita is the brand of choice at BTHFT, Humira can only be prescribed if approved by DTC.
TA187: Infliximab and adalimumab for the treatment of Crohn's disease
TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
|
10.01.03 |
Adalimumab Amgevita |
Amgevita is brand of choice at BTHFT. Humira should only be prescribed if approved to do so by DTC.
To be prescribed as per NICE guidelines:
- NICE TA 375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA 373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA 195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- NICE TA 199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Monitoring guidance can be found:
|
13.05.03 |
Adalimumab Amgevita |
TA146: Adalimumab for the treatment of adults with psoriasis
TA187: Infliximab and adalimumab for the treatmetn of Crohn's disease
TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
|
13.05.03 |
Adalimumab Amgevita |
Amgevita is brand of choice at BTHFT. Humira should only be prescribed if approved to do so by DTC.
To be prescribed as per NICE guidelines:
TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
TA146: Adalimumab for the treatment of adults with psoriasis
TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
|
13.06.01 |
Adapalene Epiduo® |
Contains adapalene 0.1% and benzoyl peroxide 2.5%
Gel |
13.06.01 |
Adapalene Differin® |
Cream and Gel |
09.06.04 |
Adcal D3 Dissolve® |
- Colecalciferol 400 units + calcium carbonate 1500mg per tablet
- For patients who cannot chew or swallow tablets or for giving via an enteral tube
|
09.06.04 |
Adcal D3® |
- Colecalciferol 400 units (10 micrograms) + calcium carbonate 1500mg (calcium 600mg) per tablet
|
09.06.04 |
Adcal D3® Caplets |
- Colecalciferol 200 units (5 micrograms) + calcium carbonate 750mg (calcium 300mg) per caplet
- For patients who cannot tolerate Adcal D3 chewable tablets but can swallow tablets
|
05.03.03 |
Adefovir Dipivoxil Hepsera® |
|
02.03.02 |
Adenosine |
Injection
Secondary care only |
24.01 |
Adrenaline |
Indication
Acute hypotension
Dose
Consider starting at 0.1micrograms/kg/min. Higher doses up to 1.5 micrograms/kg/minute have been used in acute hypotension
For further information see Y&H ODN formulary - Scroll to top
Administration
Continuous IV infusion via central line.
USE GUARDRAILS ON INFUSION PUMP
Syringe concentration - 3000 microgram in 50 ml 5% or 10% glucose. (60micrograms/ml)
Monitoring
BP, Heart rate, Peripheral perfusion, Blood sugars, Blood gas
Further Info
CHECK STRENGTH OF AMPOULE!
See " Cardiovascular support in neonates" guideline
Supply
Available from pharmacy as a stock item as vials. DSU can make named patient syringes on request during normal working hours. Contact ward pharmacist |
02.07.03 |
Adrenaline / Epinephrine |
Injection
Adult dose is 10ml of 1:10,000 given IV (Note: For anaphylaxis the dose is 0.5ml of 1:1,000 given IM ).
|
03.04.03 |
Adrenaline / Epinephrine |
Injection
Treatment of anaphylaxis
|
03.04.03 |
Adrenaline / Epinephrine |
|
03.04.03 |
Adrenaline / epinephrine EpiPen® |
Treatment of anaphylaxis
|
08.01.05 |
Afatinib |
|
08.01 |
Aflibercept Zaltrap® |
|
11.08.02 |
Aflibercept Eylea® |
Intravitreal injection |
04.03.04 |
Agomelatine |
Tablets 25mg
Usual dose range 25-50mg daily
Max daily dose 50mg
Max single dose 50mg |
09.02.02.02 |
Albumin Solution |
|
13.11.01 |
Alcohol |
|
06.06.02 |
Alendronic Acid |
Tablet 70mg
70mg once WEEKLY dose
|
06.06.02 |
Alendronic acid Binosto® |
- Restricted for use in patients with true swallowing difficulties (e.g. strictures) or those truly intolerant of bisphosphonate tablets despite the addition of a PPI.
|
09.06.04 |
Alfacalcidol |
|
15.01.04.03 |
Alfentanil |
|
09.08.01 |
Alglucosidase Alfa Myozyme® |
|
02.12 |
Alirocumab Praluent® |
For use in line with NICE TA393 |
02.05.05.03 |
Aliskiren |
Tablet
for specialist cardiology initation only |
13.05.01 |
Alitretinoin Toctino® |
Capsules
Dermatology specialist use only
Restricted to use in adult patients with severe chronic hand eczema unresponsive to treatment with potent topical corticosteroids in accordance with NICE TAG 177.
|
10.01.04 |
Allopurinol Zyloric® |
|
10.01.04 |
Allopurinol |
|
09.06.05 |
Alpha Tocopheryl Acetate |
|
07.04.05 |
Alprostadil Caverject® |
Intracavernosal Injection |
07.04.05 |
Alprostadil MUSE® |
Urethral application |
24.01 |
Alprostadil Prostin VR |
Indication:
Open/maintain patency of the ductus arteriosus
Dose:
12.5-100 nanograms/kg/min But higher doses may be used e.g. 200 nanograms/kg/min If well start at 12.5 or 25 nanograms/kg/min Unwell babies with ?duct dependent problem expect to need ventilation, start at 100nanograms/kg/min See regional guidance link
Administration
USE GUARDRAILS ON INFUSION PUMP
Syringe concentration - 300micrograms in 50ml in 5% glucose
See guide line in link below for more infomation.
Monitoring
Watch for apnoea(especially in U&E, bloods sugars, reflux.
Further Info:
See Y&H ODN guidline in link below Undiluted solution must NOT come into contact with the barrel of the plastic syringe; add the required volume of alprostadil to a volume of infusion fluid in the syringe and then make up to final volume.
Supply:
Available on NNU as a stock item. Stored in fridge.
Available from Pharmacy DSU on named patient request during normal hours. Contact ward pharmacist |
02.10.02 |
Alteplase |
Injection (secondary care only)
Actilyse®
Actilyse Cathflo®. For thrombolytic treatment of occluded venous access devices only |
11.99.99.99 |
Alteplase intravitreal injection |
Intravitreal injection 25microgram in 0.1mL
|
13.12 |
Aluminimum Chloride Hexahydrate 20% in Alcoholic Base Driclor® |
|
13.12 |
Aluminimum Salts |
|
01.02 |
Alverine Citrate Spasmonal® |
Capsules, 60mg and 120mg (forte) |
04.09.01 |
Amantadine Hydrochloride Symmetrel® |
|
05.01.04 |
Amikacin |
|
24.01 |
Amikacin |
Indication: Gentamicin resistant gram negative bacilli
Dose: 15mg/kg 36 hourly in babies < 32 weeks
15mg/kg 24 hourly for all other neonates and infants
20mg/kg may be needed in severe sepsis
Administration
See Medusa IV guide for information on administration - Scroll to top
Monitoring
Renal function The target trough is <5mg/L
Sample should be taken 6 hours prior to 3rd dose. Repeat daily until stable, then every 3 doses.
Redose patient at 24 hours if trough level achieved. If trough is high, recheck level 12 hours after that level was taken and redose after that if level in range.
Further Info:
Nephrotoxicity may be increased by concurrent administration of amphotericin and potent diuretics.
Supply: Available from pharmacy on a named patient request. |
02.02.03 |
Amiloride Hydrochloride |
Tablet 5mg, Oral solution 5mg/5ml
Tablets can be crushed and dispersed in water if necessary |
03.01.03 |
Aminophylline Phyllocontin Continus® |
Tablets M/R 225mg
350mg tablets not stocked at BTHFT |
03.01.03 |
Aminophylline IV |
Injection, 25mg/ml |
02.03.02 |
Amiodarone |
Tablet, Injection (secondary care only)
Tablets can be crushed and mixed with water |
04.02.01 |
Amisulpride |
|
04.03.01 |
Amitriptyline |
|
02.06.02 |
Amlodipine |
Tablet
If needed tablets can be crushed and dispersed in water.
Amlodipine Oral Solution restricted for those patients with established swallowing difficulties or NG tube administration |
13.10.02 |
Amorolfine Loceryl® |
|
05.01.01.03 |
Amoxicillin |
|
24.01 |
Amoxicillin |
Indication
Infection - broad spectrum
Dose
IV:30-60 mg/kg/dose every 12 hours <7 days of age
IV:30-60/kg/dose every 8 hours >7 days of age
Oral: 30mg/kg/dose every 8 hours >7days of age
Administration
See Medusa IV guide for information on administration - Scroll to top
IV doses over 30mg/kg to be given by IV infusion over 30minutes
Monitoring
Renal function
Further Info:
Active againist: listeria, haemophyllus, enterococci, streptococci, pneumococci, salmonella,shigella and many coliforms
Supply:
Available on NNU as a stock item. Oral to be ordered on a named patient request. |
05.02 |
Amphotericin AmBisome® |
|
24.01 |
Amphotericin (liposomal) Ambisome® |
Indication
Systemic fungal infections
Dose
All ages, give a test dose of 100microgram/kg, to a maximum of 1mg, over 10 minutes. Maintenence dose can be given 1 hour after test dose.
1mg/kg once a day, increased if necessary, to 3mg/kg once a day.
Administration IV infusion over at least 30 minutes. Amphotericin MUST be diluted in Glucose 5% for infusion. Final concentration in neonates must be 1mg/ml Lines MUST be flushed with Glucose 5% ONLY. A test dose of 100micrograms over 10 minutes may be considered in older babies to reduce risk of anaphaylaxis.
See Medusa IV guide for information on administration - Scroll to top
Monitoring Renal function Potassium
Further Info
Prescribe as “Amphotericin liposomal (AmBisome)”
Active against aspergillosis, candidasis, coccidoidomycosis and cryptococcosis.
Supply: Vials are available from pharmacy as a named patient supply. |
08.01.05 |
Amsacrine Amsidine® |
|
09.01.04 |
Anagrelide |
Capsule
On Haematologist advice only.
|
10.01.03 |
Anakinra Kineret® |
Prefilled syringe 100mg (subcut)
Daily dose |
08.03.04.01 |
Anastrozole |
|
12.03.01 |
Antacid with Oxetacaine |
Each 5ml contains 10mg Oxetacaine, Aluminium hydroxide equivalent to 200mg aluminium oxide + 100mg magnesium hydroxide
Indicated for painful swallowing, during and following radiotherapy to the head & neck and chest areas. Should be reserved for patients with oral mucositis and oesophageal lesions which are causing painful swallowing. Consider the use of a simple antacid first line. |
11.04.02 |
Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin® |
|
14.05.03 |
Anti-D (Rh0) Immunoglobulin Rhophylac® |
|
08.02.02 |
Anti-human thymocyte immunoglobulin (rabbit) Thymoglobuline® |
|
01.07.01 |
Anusol® |
Ointment, Cream, Suppositories |
02.08.02 |
Apixaban |
Tablets 2.5mg amd 5mg
POSITION STATEMENT TO ADD |
04.09.01 |
Apomorphine |
|
11.08.02 |
Apraclonidine Iopidine® |
|
08.02 |
Apremilast Otezla® |
For use in line with NICE TA419 |
13.05.03 |
Apremilast Otezla |
Oral tablets
As per NICE guidelines:
TA419:Apremilast for treating moderate to severe plaque psoriasis
TA433: Apremilast for treating active psoriatic arthritis |
04.06 |
Aprepitant Emend® |
Capsules
For oncology patients only
|
13.02.01 |
Aqueous Cream BP |
Cream
Not recommended for use in children
Only use a soap substitute, not as a moisturiser |
04.02.01 |
Aripiprazole Abilify® |
Tablet
Dispersible tablets
Liquid
Injection (IM use)
Injection (prolonged release suspension for injection)
|
08.01.05 |
Arsenic Trioxide Trisenox® |
|
15.02 |
Articaine Hydrochloride with Adrenaline Septanest® |
|
09.06.03 |
Ascorbic Acid |
Tablets 50mg, 100mg, 200mg, 500mg
|
04.07.01 |
Aspirin |
Tablet dispersible and E/C, 75mg and 300mg, Suppository
|
02.09 |
Aspirin (antiplatelet) |
Tablets - dispersible and EC, (Suppository - Named patient use)
Enteric coated aspirin is second line to dispersible aspirin in line with UKMI Q&A below
For recommendation for use of aspirin in pregnant women at high risk of pre-eclampsia see NICE CG107.
|
05.03.01 |
Atazanavir Reyataz® |
specialist consultant |
02.04 |
Atenolol |
Tablet, Liquid, (Injection - secondary care only) |
04.04 |
Atomoxetine Strattera® |
Capsules 10mg and 40mg
Drug treatment of attention deficit hyeractivity disorder (ADHD)
Usual dose range 80mg-100mg
Max daily dose 120mg (unlicensed)
Max single dose 120mg (unlicensed) |
02.12 |
Atorvastatin |
Tablets
If needed tablets can be crushed and dispersed in water |
07.01.03 |
Atosiban Tractocile® |
Injection 7.5mg/ml |
24.01 |
Atracurium |
Indication: Short acting muscle relaxant
Dose A 500microgram/kg stat dose can produce muscle relaxation for up to 30 mins.
A continuous infusion of 300-500micrograms/kg/hour will provide continual neuromuscular blockade in neonates. Some mat need
Administration
USE GUARDRAIL INFUSION PUMP
Syringe Concentration 25mg in 25mls (1mg/ml).
Infusions made up in glucose 5% need to be made up every 8 hours, while those in sodium chloride 0.9% can be changed every 24 hours.
See Medusa IV guide for information on administration - Scroll to top
Monitoring
U&E, temperature,
Further Info: In babies requiring paralysis consider sedation and pain relief were necessary.
Supply: Available from pharmacy as a stock item. Stored in fridge |
15.01.05 |
Atracurium Besilate |
|
15.01.05 |
Atracurium Besilate Tracrium® |
|
15.01.03 |
Atropine |
|
18 |
Atropine |
|
11.05 |
Atropine Sulphate |
Eye drops 0.5% and 1%, Minims 1% |
10.01.03 |
Auranofin Ridaura® |
|
07.04.05 |
Avanafil Stendra® |
|
13.02.01 |
Aveeno® |
Cream, Bath oil |
08.01.03 |
Azacitidine Vidaza® |
|
01.05.03 |
Azathioprine |
Tablets 25mg, 50mg, Suspension SF 50mg/5ml
|
08.02.01 |
Azathioprine |
|
10.01.03 |
Azathioprine |
|
13.05.03 |
Azathioprine |
Oral treatment
SWYAPC shared care guidelines |
11.04.02 |
Azelastine Optilast® |
Eye drops 0.05% |
05.01.05 |
Azithromycin |
|
11.03.01 |
Azithromycin Azyter® |
eye drops single use 1.5% |
24.01 |
Aztreonam |
Indication
Infection- limited to Gram-negative aerobic bacteria Pseudomonas aeruginosa, Neisseria meningitidis, Neisseria gonorrhoeae and Haemophilus influenza.
Dose
30 mg/kg/dose every 12 hours in preterm 30 mg/kg/dose every 8 hours in term <7days 30 mg/kg/dose every 6-8 hours in term neonates >7days Reduce dose in renal impairment see additonal resources for dose adjustment.
Administration
See Medusa IV guide for information on administration - Scroll to top
Monitoring
U&E, LFT, FBC
Further Info: Supply: Available from pharmacy on named patient request. |
05.01.02.03 |
Aztreonam nebuliser solution Cayston® |
|
10.02.02 |
Baclofen |
|
12.02.03 |
Bactroban Nasal® Mupirocin 2% in White Soft Paraffin |
Nasal ointment
- July 2014 - ongoing manufacturing problem - use naseptin as an alternative (check for peanut allergy)
- MRSA suppression: Three times daily for 5 days
|
01.05.01 |
Balsalazide Sodium Colazide® |
Capsules 750mg |
13.02.02 |
Barrier preparation Metanium® |
|
13.02.02 |
Barrier preparation Siopel® |
Cream |
13.02.02 |
Barrier preparation Sudocrem® |
|
08.02.04 |
BCG bladder instillation OncoTICE® |
|
14.04 |
BCG vaccine Intradermal |
|
03.02 |
Beclometasone Clenil Modulite® |
Aerosol Inhaler
Available strengths 50mcg/dose, 100mcg/dose, 200mcg/dose and 250mcg/dose |
03.02 |
Beclometasone Qvar® |
Aerosol and Breath-actuated inhaler
Prescribe by brand
Aerosol 50mcg/dose, 100mcg/dose
Easi-breathe 50mcg/dose, 100mcg/dose
Autohaler not stocked within BTHFT
Qvar is not interchangeable with other CFC-free beclometasone inhalers, Qvar is approximately twice as potent as Clenil |
03.02 |
Beclometasone and formoterol Fostair® |
Aerosol Inhaler
Beclometasone 100 micrograms and formoterol 6 micrograms |
12.02.01 |
Beclometasone Dipropionate |
Nasal spray 50micrograms per spray
|
03.02 |
Beclometasone with formoterol and glycopyrronium Trimbow® |
|
08.01.01 |
Bendamustine |
|
02.02.01 |
Bendroflumethiazide |
Tablet 2.5mg
If needed tablets can be dispersed in water
|
20 |
BENZBROMARONE Tablets 100 mg, 50mg |
FORM AND STRENGTH: 100mg Tablet
INDICATION: Gout where intolerant/allergic to allopurinol and febuxostat
DOSE: 100mg daily
PACK SIZE:
SUPPLIER: IDIS
LICENSE TYPE: Licensed in Germany
PRESCRIBING CONSULTANT: Dr Helen McIver (13/11/2013) |
13.06.01 |
Benzoyl Peroxide |
|
13.06.01 |
Benzoyl Peroxide 5% with Clindamycin 1% Duac® Once Daily |
Cream |
12.03.01 |
Benzydamine Difflam® |
Oral rinse, Spray
|
05.01.01.01 |
Benzylpenicillin Crystapen® |
|
05.01.01.01 |
Benzylpenicillin Benzathine |
|
24.01 |
Benzylpenicillin Sodium |
Indication
Empirical treatment of early onset neonatal sepsis. Active againist streptococcal(including pneumococcal), gonococcal, and meningococcal infections
Dose
50 mg/kg/dose every 12 hours
50 mg/kg/dose every 8 hours 7-28 days
50 mg/kg/dose every 6 hours >28 days
For further information see Y&H ODN formulary - Scroll to top
Administration
Slow IV bolus or infusion over 15–30 minutes. Longer administration time is particularly important when using doses of 50 mg/kg (or greater) to avoid CNS
See Medusa IV guide for information on administration - Scroll to top
Monitoring Renal function
Further Info Consider reducing dose to 25mg/kg/dose in moderate to severe renal failure. Seek senior advice.
Supply: Available from pharmacy as a stock item |
04.06 |
Betahistine Dihydrochloride |
Tablet 8mg and 16mg
If needed tablets can be crushed and dispersed in water. More Info
|
13.04 |
Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic® |
Ointment, scalp lotion
Potent
For thick plaque psoriasis |
13.04 |
Betamethasone (as Valerate) 0.025% Betnovate-RD® |
Cream, Ointment
Moderate
|
13.04 |
Betamethasone (as Valerate) 0.1% Betnovate® |
Cream, Ointment, Scalp application, Lotion
Potent
|
13.04 |
Betamethasone (as Valerate) 0.1% with Clioquinol Betnovate-C® |
Ointment, Cream
Potent with antimicrobial
Now available generically but more expensive than before approx £19 for 30g
|
13.04 |
Betamethasone (as Valerate) 0.1% with Neomycin Sulphate 0.5% Betnovate-N® |
|
12.01.01 |
Betamethasone 0.1% with Neomycin 0.5% ear drops |
|
11.04.01 |
Betamethasone 0.1% with Neomycin 0.5% eye drops Betnesol N® |
Drops - Can be used for eye,ear and nose |
12.01.01 |
Betamethasone ear drops |
Drops 0.1%
|
11.04.01 |
Betamethasone eye ointment Betnesol® |
Eye ointment 0.1% |
11.04.01 |
Betamethasone eye, ear, nose drops Vistamethasone® |
Drops 0.1%- for the eye, ear & nose |
12.02.01 |
Betamethasone nasal drops |
Drops 0.1%
|
11.06 |
Betaxolol Betoptic® |
0.5% Eye drops
|
08.01.05 |
Bevacizumab Avastin® |
|
11.08.02 |
Bevacizumab intravitreal injection Avastin® |
|
02.12 |
Bezafibrate |
Immediate release tablets, 200mg
Modified release tablets, 400mg |
08.03.04.02 |
Bicalutamide |
|
11.06 |
Bimatoprost Lumigan® |
Eye drops 0.01% and 0.03%
For those patients where pressure reduction has been inadequate on latanoprost
|
11.06 |
Bimatoprost with Timolol Ganfort® |
Eye drops |
09.08.01 |
Biotin |
|
06.01.01.02 |
Biphasic Insulin Aspart NovoMix® 30 |
- 10mL vial, 3mL cartridge, 3mL prefilled pen
|
06.01.01.02 |
Biphasic Insulin Lispro Humalog® Mix |
Available as Mix25 and Mix50.
3mL cartridge, 3mL prefilled pen (KwikPen)
|
06.01.01.02 |
Biphasic Isophane Insulin Hypurin® Porcine 30/70 Mix |
|
06.01.01.02 |
Biphasic Isophane Insulin Humulin® M3 |
- 10mL vial, 3mL cartridge, 3mL prefilled pen
- First choice in type II diabetes
|
06.01.01.02 |
Biphasic Isophane Insulin Insuman® Comb |
Available as Comb 15, Comb 25, and Comb 50
|
01.06.02 |
Bisacodyl |
Tablet e/c 5mg, Suppository 10mg |
02.04 |
Bisoprolol |
Tablet
First line use for heart failure
If needed tablets can be crushed and dispersed in water
|
02.08.01 |
Bivalirudin |
Injection (secondary care only)
Restricted to use in accordance with NICE TAG 230 and CG94. Consultant recommendation only.
|
08.01.02 |
Bleomycin |
|
08.02.03 |
Blinatumomab Blincyto® |
For use in line with NICE TA450 |
05.03.03 |
Boceprevir Victrelis® |
|
13.08.01 |
Borderline Substances Anthelios® |
Cream
Highest UVA/UVB protection
Preservative and perfume free |
08.01.05 |
Bortezomib Velcade® |
|
08.01.05 |
Bosutinib Bosulif® |
|
04.09.03 |
Botulinum Toxin Type A Botox® |
Prescribe by brand
Units are not equivalent |
04.09.03 |
Botulinum Toxin Type A Dysport® |
Prescribe by brand
Units are not equivalent |
04.09.03 |
Botulinum Toxin Type A Xeomin® |
|
08.01.05 |
Brentuximab vedotin Adcetris® |
To be used in line with NICE guidance |
11.06 |
Brimonidine Tartrate |
Eye drops 0.2% |
11.06 |
Brimonidine Tartrate 0.2% with Timolol 0.5% Combigan® |
Eye drops |
11.06 |
Brinzolamide Azopt® |
Eye drops 10mg/ml |
11.06 |
Brinzolamide 1% with Timolol 0.5% Azarga® |
Eye drops |
13.05.03 |
Brodalumab Kyntheum |
To be prescribed as per NICE guidelines:
TA511: Brodalumab for treating moderate to severe plaque psoriasis |
04.09.01 |
Bromocriptine |
|
06.07.01 |
Bromocriptine |
Tablets 1mg and 2.5mg |
01.05.02 |
Budesonide Budenofalk® |
- 3mg gastro resistant capsules
|
01.05.02 |
Budesonide Cortiment |
- Cortiment 9mg prolonged release tablets
- Once daily preparation
|
01.05.02 |
Budesonide Jorveza® |
- 1mg orodispersible tablet
- Restricted for use by gastroenterology only for eosinophilic oesophagitis
|
01.05.02 |
Budesonide Entocort® |
- 3mg modified release capsules
|
03.02 |
Budesonide Pulmicort® |
Dry powder inhaler, Nebules
Pulmicort turbohaler stocked at BTHFT, 100mcg/dose and 200mcg/dose
Easyhaler brand not stocked
Nebules 500mcg/2ml and 1mg/2ml
|
12.02.01 |
Budesonide |
Nasal spray 64micrograms per spray
|
03.02 |
Budesonide and formoterol Symbicort® |
Dry powder inhaler (Turbohaler)
|
02.02.02 |
Bumetanide |
Tablet 1mg and 5mg, Liquid 1mg/5ml,
Liquid - very expensive. Tablets can be crushed and mixed with water as an alternative.
Injection 0.5mg/ml - no longer available, use furosemide IV if necessary
1 mg oral bumetanide is roughly equivalent to 40 mg oral furosemide |
15.02 |
Bupivacaine Hydrochloride |
|
15.02 |
Bupivacaine with Fentanyl |
|
04.07.02 |
Buprenorphine BuTrans® patch |
Patch (Weekly patch)
Only for patients where other options eg codeine, tramadol or low dose morphine have been exhausted. Morphine preferred if a strong opioid needed.
When compared to other opiates Butrans® patches are weak and expensive
|
04.07.02 |
Buprenorphine Temgesic® |
|
04.07.02 |
Buprenorphine Transtec® patch |
Patch
Change every 4 days (96 hours) |
04.10.03 |
Buprenorphine Subutex® |
Sublingual tablets 400mcg, 2mg and 8mg
Substance misuse
Usual dose range 2-24mg
Always confirm with patients substance misuse service or regular community pharmacy to confirm the dose before prescribing. Contact details for Bradford Substance Misuse:
Bradford Substance Misuse Directory
|
04.10.03 |
Buprenorphine and Naloxone Suboxone® |
Sublingual Tablets 2mg/0.5mg and 8mg/2mg
Substance misuse
Usual dose range 2-24mg
Always confirm with patients substance misuse service or regular community pharmacy to confirm the dose before prescribing. Contact details for Bradford Substance Misuse:
Bradford Substance Misuse Directory
|
04.10.02 |
Bupropion Hydrochloride Zyban® |
|
08.03.04.02 |
Buserelin |
|
08.01.01 |
Busulfan |
|
03.04.03 |
C1 Esterase Inhibitor Berinert® |
|
03.04.03 |
C1 esterase inhibitor Cinryze® |
|
08.01.05 |
Cabazitaxel Jevtana® |
Available Via CDF for following
2nd line treatment of advanced castration resistant prostate cancer following docetaxel based regimen
3rd line treatment of advanced castration resistant prostate cancer following docetaxel and abiraterone based treatment |
04.09.01 |
Cabergoline |
|
06.07.01 |
Cabergoline |
Tablets 500microgram |
24.01 |
Caffeine CITRATE |
Indication
Neonatal apnoea
Dose
Loading - 20mg/kg once a day. IV to be given over 30min
Maintenance - 10 mg/kg once a day. IV to be given over 10min.
IV = PO dose
Administration
See Medusa IV guide for information on administration - Scroll to top
Monitoring Levels (not routinely needed) 75-150 mmol/litre
Further Info
Prescribed as CAFFEINE CITRATE only
Supply
Available from pharmacy as stock item |
13.03 |
Calamine |
lotion, with aqueous cream |
13.05.02 |
Calcipotriol Dovonex® |
|
13.05.02 |
Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet® |
Gel, Ointment |
06.06.01 |
Calcitonin (salmon) / Salcatonin |
Injection |
09.06.04 |
Calcitriol |
|
13.05.02 |
Calcitriol 3micrograms/g Silkis® |
|
09.05.02.02 |
Calcium Acetate Phosex® |
Tablets
Generally recommended as first line phosphate binder. More effective than calcichew and less elemental calcium.
|
09.05.02.02 |
Calcium Carbonate |
Tablets
Calcium-based phosphate binders may be used as the initial binder therapy for patients with chronic kidney disease as they are cheap and relatively efficacious, in conjunction with dietary phosphate restriction, to control phosphorus and parathyroid levels.
If hypercalcaemia develops with the use of calcium carbonate, it may be necessary to convert to calcium acetate, a non calcium-containing phosphate binder, or a combination of both.
|
09.05.01.01 |
Calcium carbonate with calcium lactate gluconate Calvive |
Calvive 1000 effervescent tablets (replacement for Sandocal)
Electrolyte guidelines available here |
09.05.01.01 |
Calcium Chloride |
Injection 10%
Acute treatment of hypocalcaemia, see local guidance
|
08.01 |
Calcium Folinate |
|
09.05.01.01 |
Calcium Gluconate |
Injection 10%
Ca2+ approx 225micromol/ml |
24.01 |
Calcium Gluconate |
Indication
Acute hypocalcaemia
Dose
Urgent correction
0.46 mmol/kg (2 mL/kg calcium gluconate 10%) for hypocalcaemia
Maintenance
0.5 to 1mmol/kg daily, adjusted according to response, dose to be given over 24 hours, use oral route as soon as possible due to risk of extravasation.
Administration
See Medusa IV guide for information on administration - Scroll to top
USE GUARDRAILS ON INFUSION PUMP
Syringe Concentration 2.25mmol Ca in 50mL (0.045mmol/mL)
Monitoring
Potassium, Calcium and Phosphate
Further Info
Use PN "Side order" guideline for making continious infusion - search link below.
Storage & Supply
Available on NNU as a stock item |
09.05.02.02 |
Calcium salts with magnesium carbonate Osvaren® |
|
09.05.01.01 |
Calcium-Sandoz® |
Syrup - CURRENT SUPPLY ISSUES ALTERNATIVES INCLUDE CACIT EFFERVESCENT TABLETS AND SANDOCAL
calcium glubionate 1.09 g, calcium lactobionate 727 mg (calcium 108.3 mg or Ca2+ 2.7 mmol)/5 mL
|
02.05.05.02 |
Candesartan |
Tablets
If needed tablets can be crushed and dispersed in water |
13.09 |
Capasal® |
|
08.01.03 |
Capecitabine Xeloda® |
|
04.07.03 |
Capsaicin |
|
10.03.02 |
Capsaicin Zacin® |
|
10.03.02 |
Capsaicin Qutenza® |
|
02.05.05.01 |
Captopril |
Tablet, Liquid (5mg/ml and 25mg/ml
If needed tablets disperse in water. Flush enteral tubes well after administration.
NB: Absorption may be reduced if given via enteral tube that terminates in the jejunum.
|
24.01 |
Captopril |
Indication
Congestive cardiac failure and hypertension
Dose
Initailly a test dose 10 microgram/kg, If tolerated increasing to max dose of 100microgram/kg/dose every 8 hours. Older babies usually require a larger dose. Discuss with Paediatric Cardiology.
Administration
Oral - Liquid
Monitoring
Close monitoring of blood pressure essential every 1-2 hour after test dose.
Montior blood pressure regulary when on maintenance regime. Renal function
Further Info Also used to reduce proteinuria in nephrotic syndrome
Supply: Available from pharmacy on named patient request. |
04.02.03 |
Carbamazepine |
Tablets 100mg, 200mg, 400mg
Slow relase preparations also available
Liquid 100mg/5ml
Usual dose range 400mg-600mg two to three times daily
Max daily dose 1600mg
|
04.07.03 |
Carbamazepine |
|
04.07.03 |
Carbamazepine |
|
04.08.01 |
Carbamazepine |
|
04.08.01 |
Carbamazepine Tegretol® |
|
04.08.01 |
Carbamazepine Carbagen® SR |
|
04.08.01 |
Carbamazepine Tegretol® Retard |
|
06.02.02 |
Carbimazole Neo-Mercazole® |
Tablets 5mg and 20mg |
03.07 |
Carbocisteine |
Capsules 375mg, Liquid 125mg/5ml and 250mg/5ml |
11.08.01 |
Carbomer 980 eye drops |
Viscous eye drops (gel)
|
08.01.05 |
Carboplatin |
|
07.01.01 |
Carboprost Hemabate® |
Injection- secondary care only
|
09.08.01 |
Carglumic Acid Carbaglu® |
|
11.08.01 |
Carmellose |
Eye drops - unit dose 0.5% and 1%
Xailin Fresh formulary product for 0.5% unit dose drops |
08.01.01 |
Carmustine BiCNU® |
|
08.01.01 |
Carmustine Gliadel® |
|
09.08.01 |
Carnitine Carnitor® |
|
A2.05.02 |
Carobel, Instant® |
For use in infants under 1 year |
02.04 |
Carvedilol |
Tablet
|
07.04.04 |
Catheter Patency Solutions |
Sodium chloride 0.9%
Solution G
|
05.01.02.01 |
Cefaclor |
|
05.01.02.01 |
Cefalexin |
|
05.01.02.01 |
Cefotaxime |
|
24.01 |
CefoTAXime |
Indication:
Severe susceptible infections due to sensitive Gram-positive and Gram-negative bacteria
Dose 50mg/kg/dose very 12 hours in <7 days of age
50mg/kg/dose every 8 hours in >7 to 20 days of age
50mg/kg/dose every 6 hours in >21 days of age
For further information see Y&H ODN formulary - Scroll to top
Administration
See Medusa IV guide for information on administration - Scroll to top
Monitoring Renal function-consider dose reduction in severe renal failure.Consider 25mg/kg every 12 hours.
Further Info Cephalosporins are not active against enterococci, listeria, campylobacter or clostridia
Supply Available as stock from pharmacy |
05.01.02.01 |
Cefradine |
|
05.01.02.01 |
Ceftaroline Zinforo® |
|
24.01 |
CefTAZidime |
Indication
Infections due to sensitive Gram-positive and Gram-negative bacteria
Dose
50 mg/kg every 24 hours <7 days of age
50 mg/kg every 12 hours 7 to 21 days of age
50 mg/kg every 8 hours >21 days of age
Administration
See Medusa IV guide for information on administration - Scroll to top
Monitoring
Renal function
Further Info
If reduced renal fucntion extend dosage interval - see resources above for further information.
Cephalosporins are not active against enterococci, listeria, campylobacter or clostridia
Supply: Held as stock on NNU |
05.01.02.01 |
Ceftazidime with avibactam |
- For intiation by microbiology or infecious diseases team only
|
05.01.02.01 |
Ceftriaxone |
|
05.01.02.01 |
Cefuroxime |
|
11.03.01 |
Cefuroxime |
Unlicensed - prepared by aseptic unit |
13.05.03 |
Certolizumab Cimzia |
As per NICE guidelines:
TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
10.01.03 |
Certolizumab Pegol Cimzia® |
For use in line with NICE guidance |
12.01.03 |
Cerumol® |
Ear drops
(Chlorobutanol 5%, Pardichlorobenzene 2%, Arachis (peanut) oil 57.3%)
Contains peanut oil
|
03.04.01 |
Cetirizine |
Tablet 10mg, Liquid 1mg/ml |
13.02.01 |
Cetraben® |
Cream and Bath oil |
13.02.01.01 |
Cetraben®Bath additive |
Bath additive |
13.11.03 |
Cetrimide |
|
08.01.05 |
Cetuximab Erbitux® |
Available Via CDF
KRAS testing to be carried out before initiation. Test also funded by the CDF
For use in line with NICE TAs 145, 242 and 439
Patient Access Scheme available for this treatment (in line with NICE TA439)
|
04.01.01 |
Chloral Hydrate |
Tablets, cloral betaine 707 mg (≡ chloral hydrate 414 mg),
Liquid chloral hydrate 143.3 mg/5 mL
Alternative for insomnia
Usual dose range 1-2 tablets at night or 15-45mls Liquid
Max daily dose 5 tablets or 70ml liquid
Max single dose 5 tablets or 70ml liquid
|
24.01 |
Chloral Hydrate |
Indication
Short term sedation
Dose 10-30 mg/kg/dose every 8 hours reduce dose in mild to moderate hepatic impairment
Administration Oral/Enteral liquid
Monitoring
LFT and U&E
Further Info
Prescribe as when required if on initiation. May accumulate with repeated doses. Avoid in severe renal and hepatic impariment
Supply Available from pharmacy on a named pateint request |
08.01.01 |
Chlorambucil |
|
05.01.07 |
Chloramphenicol |
Ear and eye only |
11.03.01 |
Chloramphenicol |
Eye drops 0.5%, Eye ointment 1%, Minims 0.5% (preservative free)
Unlicensed use - topically to wound sutures and for bites
|
12.01.01 |
Chloramphenicol |
Ear drops 5% and 10% |
04.01.02 |
Chlordiazepoxide |
Capsules 5mg and 10mg |
12.03.04 |
Chlorhexidine Gluconate Corsodyl® |
|
13.11.02 |
Chlorhexidine gluconate 4% Hibiscrub® |
Skin antisepsis
- MRSA suppression: use once daily for duration of admission
|
12.03.02 |
Chlorhexidine Mouthwash |
|
10.01.03 |
Chloroquine |
Tablet,Syrup.
|
02.02.01 |
Chlorothiazide |
Tablets Not stocked at BTHFT
Suspension for paediatric use 250mg/5ml |
24.01 |
Chlorothiazide |
Indication
Heart failure, hyperinsulinaemic hypoglycaemia and chronic lung disease.
Dose
10 mg/kg every 12 hours.
Administration
Oral - liquid available
Monitoring
U&E Renal function
Further Info
May cause hypokalaemia and hyperuricaemia. Doses may vary from 5-20mg/kg depending on indication and specialist advice.
Supply
Available from pharmacy as a named patient request. |
03.04.01 |
Chlorphenamine |
Tablets 4mg. Liquid 2mg/5ml, Injection
can cause drowsiness |
04.02.01 |
Chlorpromazine |
Tablet 25mg, 50mg, 100mg Oral solution 25 mg/5 mL
First generation antipsychotic
Usual dose range: 75-300mg in divided doses
Max daily dose: 1000mg
Max single dose: not stated
|
24.01 |
Chlorpromazine |
Indication
Neonatal abstinence syndrome
Dose
1mg/kg every 8 hours.
Administration
Oral - liquid available
Monitoring
Blood pressure
Further Info
Dose can be doubled in severe withdrawal. Maximum dose 6mg/kg/day
Supply
Available from pharmacy as a named patient. |
04.06 |
Chlorpromazine Hydrochloride |
|
12.03.01 |
Choline Salicylate Bonjela® Adult |
For use in adults and children over 16 |
06.05.01 |
Chorionic Gonadotrophin Pregnyl® |
Injection 5000 unit ampoule |
03.02 |
Ciclesonide Alvesco® |
Aerosol Inhaler
80mcg/dose stocked at BTHFT |
01.05.03 |
Ciclosporin |
Injection 50mg/ml, capsules 10mg. 25mg and 50mg, liquid 100mg/ml- secondary care only
Ciclosporin must be prescribed by brand - Neoral stocked at BTHFT |
08.02.02 |
Ciclosporin Capimune®, Neoral® |
|
08.02.02 |
Ciclosporin |
|
10.01.03 |
Ciclosporin |
|
11.99.99.99 |
Ciclosporin |
Eye drops 0.05%
Unlicensed |
13.05.03 |
Ciclosporin Capimune |
Prescribed by brand
SWYAPC shared care guidelines |
11.99.99.99 |
Ciclosporin 0.1% eye drops Verkazia® |
- 0.3ml unit dose eye drops
- Paediatric opthalmology use only
|
11.99.99.99 |
Ciclosporin 0.1% eye drops Ikervis® |
- 0.3ml unit dose eye drops
- Adult opthalmology use only
|
09.05.01.02 |
Cinacalcet |
Tablets 30mg, 60mg and 90mg |
04.06 |
Cinnarizine |
Tablets 15mg |
05.01.12 |
Ciprofloxacin |
|
11.03.01 |
Ciprofloxacin |
Eye drops 0.3% |
12.01.01 |
Ciprofloxacin |
|
20 |
Cisapride |
FORM AND STRENGTH: Tablets 10mg
INDICATION: Prokinetic
DOSE: 10mg three to four times daily
PACK SIZE:
SUPPLIER:
LICENSE TYPE:
PRESCRIBING CONSULTANT:
DATE AUTHORISED:
|
08.01.05 |
Cisplatin |
|
04.03.03 |
Citalopram |
Tablets 10mg, 20mg and 40mg
Oral drops 40mg/ml, 4 drops (8mg) equivalent to 10mg tablet
Usual dose range 20-40mg daily
Max daily dose 40mg
Max single dose 40mg |
01.06.04 |
Citrate micro enema |
Micro-enema
|
08.01.03 |
Cladribine Litak® |
|
08.01.03 |
Cladribine |
|
05.01.05 |
Clarithromycin |
|
05.01.06 |
Clindamycin |
|
07.02.02 |
Clindamycin Dalacin® |
Cream 2%, 40g pack with 7 applicators |
13.06.01 |
Clindamycin 1% Dalacin T® |
Lotion |
04.08.01 |
Clobazam |
|
13.04 |
Clobetasol Propionate (with antimicrobials) Dermovate-NN® |
Ointment, Cream
Very Potent with antimicrobial
Now available generically but more expensive than before approx £64.00
|
13.04 |
Clobetasol Propionate 0.05% Dermovate® |
Cream, Ointment, Scalp application, Shampoo (Etrivex®)
Very potent
Prescribe by brand name (hospital only)to avoid confusion between similar sounding generic names
|
13.04 |
Clobetasone Butyrate 0.05% Eumovate® |
Cream, Ointment
Moderately potent
Prescribe by brand name (hospital only)to avoid confusion between similar sounding generic names
|
13.04 |
Clobetasone butyrate 0.05%, oxytetracycline 3%, nystatin 100,000units/g Trimovate® |
Ongoing supply problem
Cream
Contains:Clobetasone Butyrate 0.05%, Oxytetracycline 3%, Nystatin 100,000 units/g
Moderately potent with antimicrobials
|
08.01.03 |
Clofarabine Evoltra® |
VIA CDF for following
Acute lymphoblastic leukaemia in patients with relapsed/ refractory disease in whom the intent is to use treatment as a bridge to bone marrow transplantation
Acute Myeloblastic leukaemia in patients with relapsed/ refractory disease in whom the intent is to use treatment as a bridge to bone marrow transplantation
|
04.01.01 |
Clomethiazole Heminevrin® |
Cspsules 192mg clomethiazole base
alternative for insomnia
Usual dose range: 1-2 capules at night
Max daily dose 2 capsules
Max single dose 2 capsules |
06.05.01 |
Clomifene Citrate |
Tablets 50mg |
04.03.01 |
Clomipramine |
Capsules 10mg, 25mg, 50mg, 100mg Tablets m/r 75mg
Usual dose range 30-150mg in divided doses
Max daily dose 250mg
Max single dose 250mg |
04.02.03 |
Clonazepam |
|
04.08.01 |
Clonazepam |
|
04.08.02 |
Clonazepam |
Injection 1mg/ml
Management of disturbed befaviour
Max daily dose 500mcg to 2mg (6mg in 24 hours)
max single dose 2mg |
24.01 |
Clonazepam |
Indication
Continuous severe seizures resisant to routine anticonvulsants.
Dose
100 micorgram/kg every 24 hours. slow IV bolus
IV infusion, initially bolus dose as above, followed by a continuous infusion starting at 10 microgram/kg/hour. Adjust according to response, up to 60microgram/kg/hr has been used.
Administration
Slow IV injecition over 2-3minutes
Continuious infusion if recommended by specialist.
Adsorbed on PVC. If PVC apparatus used complete infusion within 2 hours
IV or PO
See Medusa IV guide for information on administration - Scroll to top
Monitoring
Respiration Salivary and bronchial hypersecretion.
Further Info
Prolonged infusion may lead to accumulaiton and delay recovery
Can be reversed by flumazenil. IV injection, 10microgram/kg repeat at 1 minute intervals to a maximum of 40microgram/kg(2mg). If necessary this may be followed by an infusion of 2-10microgram/kg/hour.
Supply
Available from pharmacy as a stock item |
02.05.02 |
Clonidine Hydrochloride |
|
02.09 |
Clopidogrel |
Tablet
If needed tablets can be dispersed in water.
|
07.02.02 |
Clotrimazole |
Cream 1%, Pessaries 500mg, 200mg and 100mg
2% cream not stocked at BTHFT, 1% cream as effective for relief of external thrush symptoms
|
12.01.01 |
Clotrimazole Canesten® |
Solution 1% |
13.10.02 |
Clotrimazole |
|
04.02.01 |
Clozapine Clozaril® |
HOSPITAL ONLY
To be initiated by consultant psychiatrist only. For treatment-resistant schizophrenia
Tablets 25mg and 100mg
Usual dose range: Adjustable initial titration (CPMS blood tests) 200-450mg
Max daily dose: Max 900mg
|
04.02.01 |
Clozapine Denzapine® |
CLOZARIL brand used within BTHFT |
04.02.01 |
Clozapine Zaponex® |
CLOZARIL brand used within BTHFT |
13.09 |
Coal Tar Extract 5% (Alcoholic) Alphosyl 2 in 1® |
|
13.05.02 |
Coal Tar in Lassars Paste |
2%, 4% & 5%
|
13.05.02 |
Coal tar lotion 5% Exorex® |
Lotion |
02.02.04 |
Co-amilofruse (furosemide and amiloride) |
Tablets
If needed tablets can be dispersed in water |
05.01.01.03 |
Co-Amoxiclav |
|
05.01.01.03 |
Co-Amoxiclav Augmentin® |
|
04.09.01 |
Co-Beneldopa Madopar®CR |
|
04.09.01 |
Co-Beneldopa Madopar® |
|
11.07 |
Cocaine |
specialist use only
4% eye drops |
04.09.01 |
Co-Careldopa Sinemet® CR |
|
04.09.01 |
Co-Careldopa Sinemet® |
|
04.09.01 |
Co-Careldopa Half Sinemet ®CR |
|
04.09.01 |
Co-Careldopa and Entacapone Stalevo® |
|
13.06.02 |
Co-Cyprindiol 2000/35 (Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms) Dianette® |
|
01.06.02 |
Co-danthramer |
Capsule 25/200mg, Suspension 25/200mg/5ml
Generally restricted for use in terminally ill patients
can colour the urine red |
01.06.02 |
Co-danthrusate |
|
01.04.02 |
Codeine |
Tablets 15mg, 30mg, 60mg and syrup (25mg/5ml) |
04.07.02 |
Codeine analgesia |
Tablet, Syrup (25mg/5mL), Injection (not recommended as no advantages over morphine and is a CD)
|
10.01.04 |
Colchicine |
|
09.06.04 |
Colecalciferol |
Colecalciferol preparations supplied for treatment of deficency only
- Plenchol 20,000 unit capsules
- Thorens 10,000 unit/ml oral drops- for children and adults with swallowing difficulties
- Maintenance doses (e.g. 1000 unit capsules) not stocked
|
02.12 |
Colesevelam |
|
01.09.02 |
Colestyramine |
Powder sachets |
02.12 |
Colestyramine |
Questran®
Questran Light®- sugar free |
05.01.07 |
Colistimethate Promixin® |
Nebulules.
Nebuliser solution for use with I-neb nebuliser
Work on repatriation of these treatments to secondary care is under discussion with NHS England. Until this work is concluded, GPs should continue to supply under shared care arrangements |
05.01.07 |
Colistimethate for nebulisation Colomycin® |
|
10.03.01 |
Collagenase Xiapex® |
|
06.04.01.01 |
Combined continuous HRT tablet Premique ® |
Premique® low dose tablet
|
06.04.01.01 |
Combined cyclical HRT tablet Elleste-Duet®, Prempak-C® |
|
07.03.01 |
Combined Hormonal Contraceptives Evra |
Patches - Ethinylestradiol with Norelgestronim
One patch to be applied weekly for 3 weeks followed by a 7 day patch-free interval |
07.03.01 |
Combined Hormonal Contraceptives TriNovum® |
|
09.02.02.01 |
Compound Sodium Lactate Intravenous Infusion |
Hartmann's Solution 500ml or 1 litre
Half Strength Hartmann's Solution
Dextrose 5% & Half Strength Hartmann's Solution 500ml polyfusor
Hartmann's Solution = Sodium Chloride 0.6%, Sodium Lactate 0.25%, Potassium Chloride 0.04%, Calcium Chloride 0.027%
|
01.04.02 |
Co-Phenotrope Lomotil® |
Tablet
contains diphenoxylate 2.5mg and atropine 25 microgrames |
05.01.08 |
Co-trimoxazole |
|
08.01.05 |
Crisantaspase Erwinase® |
|
08.01.05 |
Crizotinib Xalkori® |
|
13.03 |
Crotamiton Eurax® |
|
04.06 |
Cyclizine |
Tablets 50mg |
11.05 |
Cyclopentolate Hydrochloride |
Mydrilate® 0.5% and 1% eye drops
Minims® Cyclopentolate Hydrochloride 0.5% and 1% single use eye drops |
08.01.01 |
Cyclophosphamide |
|
06.04.02 |
Cyproterone Acetate |
Tablet 50mg |
08.03.04.02 |
Cyproterone Acetate |
|
08.01.03 |
Cytarabine DepoCyte® |
|
08.01.03 |
Cytarabine |
|
02.08.02 |
Dabigatran |
Capsules 75mg, 110mg and 150mg
Rivaroxaban is the oral anticoagulant of choice for prophylaxis of VTE following total knee and hip replacement
POSITION STATEMENT TO ADD IN REGARDS TO ROLE IN STROKE AND AF |
08.01.05 |
Dacarbazine |
|
08.02.02 |
Daclizumab Zenapax® |
|
08.01.02 |
Dactinomycin Cosmegen Lyovac® |
|
24.01 |
Dalivit |
0.6mls once daily |
02.08.01 |
Danaparoid |
Injection 1250units/ml
Can be used as an alternative in patients who have developed heparin-induced thrombocytopenia (HIT) |
06.07.02 |
Danazol |
Capsules 100mg, 200mg |
10.02.02 |
Dantrolene |
|
15.01.08 |
Dantrolene Sodium |
|
09.01.03 |
Darbepoetin Alfa |
Injection:
- Prefilled syringes
- Prefilled disposable injection device (Aranesp®SureClick)
|
07.04.02 |
Darifenacin Emselex® |
Tablet 7.5mg and 15mg |
05.03.01 |
Darunavir Prezista® |
|
08.01.05 |
Dasatinib Sprycel® |
|
08.01.02 |
Daunorubicin |
|
09.01.03 |
Deferasirox |
Dispersible tablet |
09.01.03 |
Deferiprone |
Tablet |
06.03.02 |
Deflazacort Calcort® |
Tablet 6mg |
08.03.04.02 |
Degarelix Firmagon® |
|
06.06.02 |
Denosumab Prolia® |
Shared care guideline available at - denosumab in primary care guideline
If the patient and healthcare professional opt for home administration as mentioned in the shared care guidance, the patient can be enrolled in the Prolong patient support programme.
Prolong contact details:
you in the Prolong patient support programme |
06.06.02 |
Denosumab XGEVA® |
See denosumab (Prolia®) for drug saftey information |
13.08.02 |
Dermacolor® |
|
13.02.01 |
Dermol® |
|
18 |
Desferrioxamine |
|
09.01.03 |
Desferrioxamine Mesilate |
|
15.01.02 |
Desflurane Suprane® |
|
24.02 |
Designer Fluids |
See Link
|
03.04.01 |
Desloratadine Neoclarityn® |
Tablets 5mg |
06.05.02 |
Desmopressin Noqdirna® |
Sodium should be monitored at 7 days and 1 month after starting |
06.05.02 |
Desmopressin |
DDAVP: Tablet, Nasal spray, Sublingual tablet , Injection 4mcg/ml.
Indicated for diabetes insipidus or polyuria/polydypsia. Usually tds.
Water Deprivation test single dose - see protocol below
Desmotabs: Indicated for primary nocturnal enuresis. Usually once daily.
Octim: Injection 15mcg/ml - For bleeding episodes in responding patients with mild haemophilia A, Von Willebrands Disease and platelet function disorders. (Nasal spray Non-Formulary)
|
06.03.02 |
Dexamethasone |
Tablets 0.5mg, 2mg, oral solution 2mg/5ml
Dexamethasone 2mg/5ml liquid is used for 500mcg and 1mg doses of dexamethasone
Dexamethasone 2mg Tablets are used for doses 2mg and above
|
24.01 |
Dexamethasone BASE |
Indication
Ventilator dependent chronic lung disease(CLD)
Dose
Prescribe and dose as Dexamethasone BASE
Individualised dosing after discussion with consultant. Doses have ranged from 50micrograms/kg/ alternate days to 500micrograms/kg/day in divided doses.
See Neonatal Formulary for further information if required
Administration
IV or PO
See Medusa IV guide for information on administration - Scroll to top
Monitoring
Blood sugars, Blood pressure, Renal function, Liver function, GI side effects
Further Info
IV may be diluted in sodium chloride 0.9% or glucose 5% to aid administration
Supply
Available from pharmacy as a stock item |
11.04.01 |
Dexamethasone eye drops |
Eye drops 0.1% and single dose minims 0.1% |
11.04.01 |
Dexamethasone intravitreal implant Ozurdex® |
|
12.01.01 |
Dexamethasone with Antibacterial Otomize® |
Ear spray
(Dexamethasone 0.1%, Neomycin Sulphate 3250 units per mL and Glacial Acetic Acid 2%)
|
12.01.01 |
Dexamethasone with Antibacterial Sofradex® |
Drops (Dexamethasone 0.05%, Framycetin Sulphate 0.5%, Gramicidin 0.005%)
Treatment of otitis externa
|
11.04.01 |
Dexamethasone with Antibacterials Sofradex® |
Drops (ear or eye)
Dexamethasone (as sodium metasulphobenzoate) 0.05% Framycetin sulfate 0.5%
Gramicidin 0.005% |
11.04.01 |
Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol® |
Eye drops, Eye ointment
Generally prescribed post surgery
|
04.04 |
Dexamfetamine |
Tablets 5mg
Drug treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Usual dose range 2.5mg - 5mg TDS (1mg/kg)
max daily dose 20mg
max single dose 5mg |
15.01.04.04 |
Dexmedetomidine |
|
04.07.02 |
Diamorphine |
Injection |
04.01.02 |
Diazepam |
Tablets 2mg, 5mg and 10mg. Oral suspension 2mg/5ml
Usual dose range: 2-10mg three times daily
Max daily dose 30mg
Max single dose 10mg |
04.08.02 |
Diazepam |
|
10.02.02 |
Diazepam |
Tablets 2mg, 5mg, 10mg
Liquid 2mg/5ml |
15.01.04.01 |
Diazepam |
|
24.01 |
Diazepam |
Indication
Sedation and Seizures
Dose
200mg/kg/dose repeated after 10 minutes if necessary.
Administration
Slow IV bolus if given IV
IV can be given orally or rectally
See Medusa IV guide for information on administration - Scroll to top
Monitoring hypotension, apnoea, respiratory depression, urinary retention,gastro-intestinal disturbances
Further Info: Use Diazemuls band only for IV injection, less irritant than other brands.
Can be reversed by flumazenil. IV injection, 10microgram/kg repeat at 1 minute intervals to a maximum of 40microgram/kg(2mg). If necessary this may be followed by an infusion of 2-10microgram/kg/hour.
Supply: Available from pharmacy as a stock item |
06.01.04 |
Diazoxide Eudemine® |
For specialist use only |
10.01.01 |
Diclofenac |
Following Drug Safety Updates the use of diclofenac is restricted to use where the risks and benefits of continued treatment have been considered (see MHRA Drug Safety Updates below)
- Suppositories available: 12.5mg, 25mg, 50mg, 100mg
|
11.08.02 |
Diclofenac Voltarol® Ophtha |
|
13.08.01 |
Diclofenac Solaraze® |
|
11.08.02 |
Diclofenac Sodium Voltarol® Ophtha multidose |
|
18 |
Dicobalt edetate |
|
01.02 |
Dicycloverine |
Tablets 10mg and 20mg, Liquid 10mg/5ml |
08.03.01 |
Diethylstilbestrol |
|
02.01.01 |
Digoxin |
Tablets 62.5mcg, 125mcg and 250mcg, Elixir 50mcg/ml, Injection 250mcg/ml (secondary care only)
Bioavailability’s are approximately: Injection 100%, Liquid 80%, Tablets 70%
|
24.01 |
Digoxin |
REVIEW?
Indication:
Supraventricular tachycardia
Dose:
Total loading dose
given as ½ immediately
¼ at 8 hours
¼ at 16 hours
>2.5kg total loading dose:
IV = 35 micrograms/kg
oral = 45 micrograms/kg
>2.5kg oral maintenance dose:
10 micrograms/kg od
For low birth weight babies see Neonatal Formulary
Administration
IV or Oral
Monitoring
Potassium, renal function, arrhythmias, conduction disturbances, thrombocytopenia.
The plasma-digoxin concentration should be maintained in the range 0.8–2 micrograms/litre. Blood should be taken at least 6 hours after a dose
Further Info:
Hypokalaemia predisposes the child to digitalis toxicity.
Supply:
Available from pharmacy as a named pateint.
Liquid suppled as 50micrograms in 5mls (10micrograms/ml)
Always check dose carefully because an overdose can cause death.
|
02.01.01 |
Digoxin specific antibody fragments Digifab® |
DigiFab® replaces Digibind® (Dec 2011).
Click here for Digifab SPC
Very rarely needed and extremely expensive. Discuss with the National Poisons Centre (08448920111) first, then with Medicines Information (4598) or the on call pharmacist (via switchboard after 17:30).
Toxbase website here
|
04.07.02 |
Dihydrocodeine |
Tablet, Tablet MR, Oral solution, injection
Injection is a CD |
02.06.02 |
Diltiazem |
Tablets, Capsules
Prescribe by brand according to medicines policy |
01.07.04 |
Diltiazem Cream 2% |
Unlicensed - available for patients unresponsive or intolerant to GTN ointment
Dose 2cm twice daily, store in fridge , 1 tube lasts one month |
13.05.03 |
Dimethyl fumarate Skilarence |
As per NICE guidelines:
TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
13.10.04 |
Dimeticone Hedrin® |
|
07.01.01 |
Dinoprostone Propess® |
Pessaries releasing 10mg over 24 hours |
07.01.01 |
Dinoprostone Prostin E2® |
IV solution 1mg/ml
Injection
Vaginal tablet (Prostin E2)
|
13.02.01 |
Diprobase® |
Cream, Ointment |
02.09 |
Dipyridamole |
Capsule MR
Secondary prevention of ischaemic stroke and TIA normally in combination with aspirin for existing patients and those unable to take clopidogrel
If needed capsules can be opened and beads mixed with water (do not crush). Flush enteral tubes well as there is potential for blockage. |
11.99.99.99 |
Disodium Edetate 0.37% |
Solution 20mL (preservative free) (Unlicensed Product)
|
20 |
Disodium Edetate 0.37% eye drops EDTA |
Solution 20ml (preservative free) (Unlicensed Product)
Specialist use only
Unlicensed request signed by Helen Devonport on behalf of Nigel James 11/06/2014
Treatment of Calcific Band Keratopathy
|
06.06.02 |
Disodium Pamidronate |
injection |
02.03.02 |
Disopyramide |
Capsule, Tablet MR, Injection (secondary care only) |
13.05.02 |
Dithranol Dithrocream® |
Cream 0.1%
Cream 0.25%
Cream 0.5%
Cream 1%
Cream 2%
|
13.05.02 |
Dithranol Ointment BP |
|
13.05.02 |
Dithranol Paste BP |
|
02.07.01 |
Dobutamine |
Infusion (secondary care only)
|
24.01 |
DoBUTamine |
Indication
Hypotension
Dose
5-20 micrograms/kg/min as continious infusion.
For further information see Y&H ODN formulary - Scroll to top
Administration
See Medusa IV guide for ADDITIONAL information on administration - Scroll to top
USE GUARDRAILS ON INFUSION PUMP
Syringe concentrations
60mg in 50mL (1200micogram/mL) SINGLE STRENGTH
120mg in 50mL (2400micogram/mL) - DOUBLE STRENGTH
Monitoring
Blood pressure(marked increase in systolic blood pressure indicates overdose) arrhythmias,dyspnoea, bronchospasm and hypokalaemia
Further Info
Compatibility information can be found on Medusa
Solutions of dobutamine may turn pink due to a slight oxidation of the drug. Such solutions are safe to use and there is no significant loss of potency.
Supply: Available from pharmacy as a standard stock |
08.01.05 |
Docetaxel Taxotere® |
|
01.06.02 |
Docusate Sodium |
Capsule 100mg, Solution 50mg/5ml (adult) 12.5mg/5ml (paediatric) |
04.06 |
Domperidone |
Tablet, Suspension, Suppository
See link below for MHRA advice about dose restrictions and contraindications
|
04.11 |
Donepezil |
Tablet 5mg, 10mg
First Line for Mild to moderate Alzheimers disease
usual dose range 5-10mg at night
max daily dose 10mg at night
Max single dose 10mg |
02.07.01 |
Dopamine |
Infusion (secondary care only)
|
24.01 |
DOPamine |
Indication
Hypotension
Dose
5-20 micrograms/kg/min as continious infusion.
For further information see Y&H ODN formulary - Scroll to top
Administration
See Medusa IV guide for ADDITIONAL information on administration - Scroll to top
USE GUARDRAILS ON INFUSION PUMP
Syringe concentrations
60mg in 50mL (1200micogram/mL) SINGLE STRENGTH
120mg in 50mL (2400micogram/mL) - DOUBLE STRENGTH
Monitoring
Blood pressure(marked increase in systolic blood pressure indicates overdose) arrhythmias,dyspnoea, bronchospasm and hypokalaemia
Further Info
Compatibility information can be found on Medusa
Supply Available from pharmacy as a standard stock |
02.07.01 |
Dopexamine |
Infusion (secondary care only)
|
03.07 |
Dornase Alfa Pulmozyme® |
Nebuliser Solution 2.5ml (pack size 30)
Expensive item, store in the fridge
Work on repatriation of these treatments to secondary care is under discussion with NHS England. Until this work is concluded, GPs should continue to supply under shared care arrangements |
11.06 |
Dorzolomide |
Eye drops 2% |
11.06 |
Dorzolomide 2% with Timolol 0.5% Cosopt® |
Eye drops |
04.03.01 |
Dosulepin |
Tablets 75mg Capsules 25mg
Usual dose range 75-225mg
Max daily dose 225mg
Max single dose 225mg in one to three divided doses |
13.02.01 |
DoubleBase® |
Doublebase gel
Dayleve gel (can be used less often than doublebase original, twice daily)
Shower gel |
03.05.01 |
Doxapram Dopram® |
Injection |
15.01.07 |
Doxapram Dopram® |
|
02.05.04 |
Doxazosin |
Tablet, Tablet MR
May be used as a 4th line option in the management of hypertension when control has not been achieved with other agents.
|
07.04.01 |
Doxazosin |
|
04.03.01 |
Doxepin |
|
13.03 |
Doxepin Hydrochloride Xepin® |
|
08.01.02 |
Doxorubicin Hydrochloride |
|
08.01.02 |
Doxorubicin Hydrochloride Caelyx® |
|
05.01.03 |
Doxycycline |
|
05.04.01 |
Doxycycline |
|
02.03.02 |
Dronedarone Multaq® |
Tablets
Restricted for cardiologist initiation in accordance with NICE guidance (TA197).
|
04.06 |
Droperidol Xomolix® |
For use by ICU and theatres only |
03.01.05 |
Drug Delivery Device Haleraid® |
For use with MDI pressurised inhalers to aid when strength in hands is impaired (eg in arthritis)
|
03.01.05 |
Drug Delivery Device Volumatic® |
Large volume device for adults and children
available with a paediatric mask
|
03.01.05 |
Drug Delivery Device AeroChamber Plus® |
Adult and children > 5 years = Blue (+/- mask)
Child 2-5 years = Yellow
Infant (6 months - 2 years) = Orange
|
03.01.05 |
Drug Delivery Device Babyhaler® |
for paediatric use
|
06.01.02.03 |
Dulaglutide Trulicity® |
0.75mg/0.5ml & 1.5mg/0.5ml pre-filled pen/pre-filled syringe
Restricted for initiation by diabetes team |
04.03.04 |
Duloxetine Cymbalta® |
Capsules 30mg and 60mg
Usual dose range 60mg daily
Max daily dose 60mg
Max single dose 60mg |
04.03.04 |
Duloxetine Yentreve® |
|
04.03.04 |
Duloxetine Cymbalta® |
Capsules 30mg and 60mg
Usual dose range 30-60mg daily
Max daily dose 120mg
Max single dose 120mg |
07.04.02 |
Duloxetine Yentreve® |
Capsule 20mg and 40mg |
13.08.01 |
Dundee reflective sun creams Dundee Block® |
|
13.05.03 |
Dupilumab Dupixent® |
To be used accordingly to NICE guidelines:
TA534: Dupilumab for treating moderate to severe atopic dermatitis |
06.04.02 |
Dutasteride Avodart® |
Capsule 500micrograms |
06.04.01.02 |
Dydrogesterone Duphaston® |
|
13.02.01 |
E45® |
Cream, Lotion, Wash emmolient |
10.02.01 |
Edrophonium Chloride |
|
09.01.04 |
Eltrombopag |
Tablet |
11.04.02 |
Emedastine Emadine® |
Eye drops 0.05% |
13.02.01.01 |
Emollient Bath Additive Aveeno® |
Bath oil |
13.02.01.01 |
Emollient Bath Additive Oilatum® |
Bath additive |
13.02.01.01 |
Emollient Bath Additive with Anitmicrobials Dermol® |
|
13.02.01 |
Emollient preparation Dermamist® |
|
06.01.02.03 |
Empagliflozin Jardiance® |
Restricted for initiation by diabetes team
Replaced use of canagliflozin and dapagliflozin
|
13.02.01 |
Emulsifying Ointment BP |
Ointment |
02.05.05.01 |
Enalapril |
Tablet
If needed tablets can be crushed and dispersed in water |
08.01.05 |
Encorafenib Braftovi® |
|
08.01.05 |
Encorafenib Braftovi® |
|
05.03.01 |
Enfuvirtide Fuzeon® |
|
02.01.02 |
Enoximone |
Injection 5mg/ml 20ml amp
Secondary care use only
Plastic apparatus should be used, crystal formation if glass used |
04.09.01 |
Entacapone Comtess® |
|
05.03.03 |
Entecavir Baraclude® |
Initiation by specialist consult only |
02.07.02 |
Ephedrine |
Injection (secondary care only)
|
12.02.02 |
Ephedrine |
Nasal drops 0.5%
Nasal drops 1%
|
08.01.02 |
Epirubicin hydrochloride |
|
02.02.03 |
Eplerenone |
Cardiology use only
Tablet 25mg and 50mg
Second line agent if spironolactone is not tolerated for use within the licensed indication of stable post MI patients with left ventricular dysfunction and clinical evidence of heart failure in line with NICE guidance.
Second line aldosterone antagonist if spironolactone is not tolerated for NYHA class II heart failure. |
09.01.03 |
Epoetin alfa Eprex® |
Injection
Restricted for haematology and renal use only
|
09.01.03 |
Epoetin beta NeoRecormon® |
Injection
Restricted for haematology and renal use only
|
02.08.01 |
Epoprostenol |
|
02.09 |
Eptifibatide |
|
04.07.04.02 |
Erenumab |
- For prophylaxis of migraine
- For initiation by neurology only as per PAS scheme
- NICE TA in development - only to be initiated by neurology team
|
09.06.04 |
Ergocalciferol |
|
07.01.01 |
Ergometrine Maleate |
Injection 500 micrograms/ml |
07.01.01 |
Ergometrine Maleate and Oxytocin Syntometrine® |
Injection ergometerine 500 micrograms and oxytocin 5units/ml |
08.01.05 |
Eribulin Halaven® |
Available via CDF if the following criteria met
Treatment of patients with locally advanced or metastatic breast cancer who have been previously treated with (or unsuitable for) an anthracycline, a taxane and capecitabine |
08.01.05 |
Erlotinib Tarceva® |
|
08.01.05 |
Erlotinib Tarceva® |
|
05.01.02.02 |
Ertapenem Invanz® |
|
05.01.05 |
Erythromycin |
|
24.01 |
Erythromycin |
Indication
Gastric reflux
Infection
Dose
12.5 mg/kg every six hours IV or Oral
3mg/kg every six hours for gastro-intestinal stasis - oral only
Administration
See Medusa IV guide for information on administration - Scroll to top Monitoring
Renal function, LFT, Long term use for reflux may cause pyloric stenosis
Further Info
2/52 course for confirmed chlamydia
Supply
Available from pharmacy as named patient. Oral liquid kept as stock. |
04.03.03 |
Escitalopram |
Tablets 5mg, 10mg, 20mg
Short term management of Generalised Anxiety Disorder
Usual dose range 10-20mg
Max daily dose 20mg
Max single dose 20mg |
02.04 |
Esmolol |
Injection (secondary care only)
|
01.03.05 |
Esomeprazole |
|
10.01.03 |
Etanercept Enbrel® |
Subcut injection 25mg and 50mg
On recommendation from specialist consultant |
13.05.03 |
Etanercept Benepali |
Benepali is brand of choice at BTFHT, Enbrel should only be prescribed if there has been prior approval from DTC.
Available as a SC injection - pen/syringes
Prescribe as per NICE guidelines psoriasis/psoriatic arthritis:
TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
05.01.09 |
Ethambutol |
|
07.03.01 |
Ethinylestradiol / levonorgestrel phased pill TriRegol®, Logynon®, Logynon®ED |
TriRegol®, Logynon®
Phasic standard strength (21 day preparation)
Logynon®ED
Phasic standard strength (28 day preparation)
Prescribe by brand, TriRegol preferred brand at BTHFT
|
07.03.01 |
Ethinylestradiol 20 mcg / norethisterone 1mg Loestrin 20® |
Monophasic standard strength (21 day preparation)
|
07.03.01 |
Ethinylestradiol 20mcg / desogestrel 150mcg Gedarel®, Mercilon® |
Monophasic low strength (21 day preparation)
Prescribe by brand, Gedarel preferred brand at BTHFT
|
07.03.01 |
Ethinylestradiol 20mcg / gestodene 75 mcg Millinette®20/75, Femodette® |
Monophasic low strength (21 day preparations) |
07.03.01 |
Ethinylestradiol 30 mcg / drospirenone 3 mg Yasmin®,Acondro® |
Monophasic Combined oral contraceptive (21 day preparation)
Prescribe by brand, Acondro preferred brand at BTHFT
|
07.03.01 |
Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel® |
|
07.03.01 |
Ethinylestradiol 30mcg / gestodene 75 mcg Millinette®, Femodene®, Femodene®ED |
Millinette®, Femodene®
Monophasic standard strength (21 day preparation)
Femodene®ED
Monophasic standard strength (28 day preparation)
Prescribe by brand, Millinette preferred brand at BTHFT
|
07.03.01 |
Ethinylestradiol 30mcg / levonorgestrel 150mcg Rigevidon®, Microgynon 30® preps, Levest®, Ovranette® |
Rigevidon®, Microgynon 30®, Levest®, Ovranette®
Monophasic standard strength (21 day preparation)
Microgynon 30 ED®
Monophasic standard strength (28 day preparation)
Prescribe by brand, Levest preferred brand at BTHFT
|
07.03.01 |
Ethinylestradiol 35 mcg / noresthisterone 500mcg Ovysmen®, Brevinor® |
Monophasic standard strength (21 day preparation)
|
07.03.01 |
Ethinylestradiol 35 mcg / norgestimate 250 mcg Cilest® |
|
04.08.01 |
Ethosuximide |
|
15.01.01 |
Etomidate Etomidate-Lipuro® |
|
15.01.01 |
Etomidate Hypnomidate® |
|
07.03.02.02 |
Etonorgestrel Nexplanon® |
Implant (subdermal) 68mg |
08.01.04 |
Etoposide Etopophos® |
|
08.01.04 |
Etoposide |
|
10.01.01 |
Etoricoxib Arcoxia® |
|
05.03.01 |
Etravirine Intelence® |
|
08.01.05 |
Everolimus Afinitor® |
Available VIA CDF |
02.12 |
Evolocumab Repatha® |
- For use in line with NICE TA394
|
08.03.04.01 |
Exemestane |
|
10.01.04 |
Febuxostat |
|
02.12 |
Fenofibrate |
Micro Capsule
Supralip 160mg is equivalent to 200mg of the other micronised brands.
|
04.07.02 |
Fentanyl Actiq® |
Lozenges 200, 400 and 600 mcicrograms |
04.07.02 |
Fentanyl |
Patch
For patients with swallowing difficulties on stable doses of opiates or on pain team specialist advice when morphine isn't suitable.
For chronic non-cancer pain, doses greater than 50 micrograms / hour by specialist recommendation or advice only.
|
15.01.04.03 |
Fentanyl |
|
24.01 |
Fentanyl |
Indication
Sedation for intubation
Dose
3 micrograms/kg/dose
Administration Take 1.0mL (50micrograms) of fentanyl and add to 4.0mL of sodium chloride 0.9%. Giving a concentration of 10micrograms in 1mL
See Medusa IV guide for information on administration - Scroll to top
Monitoring
Blood pressure, muscle rigidity and respiratory rate
Further Info: See Preparation of drugs for intubation
Supply: Available from pharmacy as a stock item IV as 50micrograms in 1ml Controlled drug. |
09.01.01.02 |
Ferric Carboxymaltose Ferinject® |
Ferinject should only be prescribed in the following clinical areas:
- Renal
- Obstetrics and gynaecology
- Paediatrics
A single dose of Ferinject should not exceed 1,000 mg of iron (20 mL) per day. Do not administer 1,000 mg of iron (20 mL) more than once a week.
For dose calculation please SPC |
09.01.01.02 |
Ferric Derisomaltose Monofer® |
Monofer should be prescribed as the IV iron of choice at BTHFT. Monofer should be prescribed in all clinical areas with an exception of renal, paediatrics, obstetrics and gynaecology.
The guideline can be found here. |
09.01.01.01 |
Ferrous Fumarate Fersamal® |
|
09.01.01.01 |
Ferrous Gluconate |
Tablet 300mg
300mg tablet = 35mg of iron. Only use if intolerent of other iron salts (but often no better)
|
09.01.01.01 |
Ferrous Sulphate |
Tablet 200mg
200mg tablets= 65mg iron
|
07.04.02 |
Fesoterodine Toviaz® |
Tablet 4mg and 8mg |
06.01.01.01 |
Fiasp® Insulin Aspart |
Rapid acting recombinant human insulin analogue
10ml vial
3ml cartridge
3ml prefilled pen
Restricted for initiation by diabetes team
For patients who require more rapid onset of action of insulin than provided by other rapid acting insulins |
05.01.07 |
Fidaxomicin Dificlir® |
|
09.01.06 |
Filgrastim Zarzio® |
|
06.04.02 |
Finasteride |
Tablet 5mg |
08.02.04 |
Fingolimod |
|
02.03.02 |
Flecainide |
Tablet, Injection (secondary care only) |
01.06.05 |
Fleet Phospho-soda® |
oral solution |
13.04 |
Flucinolone Acetonide 0.025% Synalar® |
Cream, Ointment
Potent |
05.01.01.02 |
Flucloxacillin |
|
24.01 |
Flucloxacillin |
Indication
Infection - beta-lactamase-producing staphylococci. Dose
50mg/kg every 12 hours < 7 days of age
50mg/kg every 8 hours 7 - 21 days of age
50mg/kg every 6 hours 21 - 28 days of age
IV = PO dose
For further information see Y&H ODN formulary - Scroll to top
Administration
See Medusa IV guide for information on administration - Scroll to top
Monitoring
Renal function, liver function
Further Info Supply Available from pharmacy as a stock item |
05.02 |
Fluconazole |
|
07.02.02 |
Fluconazole |
Capsule 50 mg and 150mg
150mg STAT dose
50mg daily for 7 days |
24.01 |
Fluconazole |
Indication: Systemic Candida infection Dose:
Prophylaxis - All babies with central IV access and <1kg
3 mg/kg every 72 hours if less than 14 days of age 3 mg/kg every 48 hours 2-4 weeks of age 3 mg/kg every 24 hours >4 weeks of age
Treatment
6-12 mg/kg every 72 hours if less than 14 days of age 6-12 mg/kg every 48 hours 2-4 weeks of age 6-12 mg/kg every 24 hours >4 weeks of age
Excreted unchanged in urine so extended dosage interval after first dose if poor renal function. See Evelina formulary
For further information see Y&H ODN formulary - Scroll to top
See Fungal Infection Guideline
Administration
See Medusa IV guide for information on administration - Scroll to top
Monitoring
Renal fucntion, U&E, ECG(QT prolongation)
Further Info: IV contains equivalent of 0.46mmol/kg of sodium for 6mg/kg dose.
Supply: Available from pharmacy as a stock item |
08.01.03 |
Fludarabine Phosphate Fludara® |
|
06.03.01 |
Fludrocortisone Acetate Florinef® |
Tablet 100 microgram
If needed tablets can be dispersed in water. Flush well if giving via enteral tube |
13.04 |
Fludroxycortide Haelan® |
|
15.01.07 |
Flumazenil Anexate® |
|
12.01.01 |
Flumetasone 0.02% with Clioquinol 1% Locorten-Vioform® |
Drops |
11.04.01 |
Fluocinolone intravitreal implant Iluvien® |
|
11.08.02 |
Fluorescein Sodium Minims® |
Eye drops 1% and 2% |
11.04.01 |
Fluorometholone FML® |
Eye drops 0.1% |
08.01.03 |
Fluorouracil |
|
08.01.03 |
Fluorouracil |
|
11.99.99.99 |
Fluorouracil |
Intravitreal Injection
Unlicensed - prepared by aseptic unit
|
13.08.01 |
Fluorouracil Efudix® |
|
04.03.03 |
Fluoxetine |
Capsules 20mg, 60mg (60mg capsules significantly more expensive, prescribe in multiples of 20mg where possible)
Liquid 20mg/5ml
Usual dose range 20-60mg daily
Max daily dose 60mg
Max single dose 60mg |
04.02.01 |
Flupentixol Depixol® |
Tablet 3mg (depixol)
Tablets 0.5g and 1mg (fluanxol) |
04.03.04 |
Flupentixol Fluanxol® |
Tablets 0.5mg, 1mg
Usual dose range 1-3mg
Max daily dose 3mg
Max single dose 2mg |
04.02.02 |
Fluphenazine Decanoate |
Depot injection |
04.02.01 |
Fluphenazine Hydrochloride Moditen® |
Injection (oily) 25mg/ml and 100mg/ml |
08.03.04.02 |
Flutamide |
|
03.02 |
Fluticasone Flixotide® |
Aersol inhaler and Dry powder (Accuhaler)
|
03.02 |
Fluticasone and formoterol Flutiform® |
Aerosol Inhaler
- 50mcg/5mg, 125mcg/5mcg and 250mcg/5mcg
|
03.02 |
Fluticasone and salmeterol Seretide® |
Evohaler, Accuhaler
|
12.02.01 |
Fluticasone furoate Avamys® |
Nasal Spray 27.5 micrograms per spray
|
03.02 |
Fluticasone furoate & vilanterol Revlar Ellipta® |
|
12.02.01 |
Fluticasone Propionate |
Nasal spray 50micrograms per spray
|
12.02.01 |
Fluticasone Propionate Flixonase Nasule® |
0.4ml unit dose vials (400 micrograms/unit dose) |
03.02 |
Fluticasone with umeclidinium and vilanterol Trelegy Ellipta® |
Trelegy Ellipta 92/55/22 dry powder inhaler |
09.01.02 |
Folic Acid |
Tablet, Syrup
Tablets can be crushed and dispersed. Liquid available for paediatrics.
|
02.08.01 |
Fondaparinux |
|
03.01.01.01 |
Formoterol Oxis® |
Long-acting beta-agonist
Only Oxis brand (6mcg and 12mcg) stocked at BTHFT
Use Oxis inhaler as alternative to Atimos Modulite, but counsel patient as Oxis is a dry powder inhaler
|
04.06 |
Fosaprepitant Ivemend® |
|
04.07.04.02 |
Fremanezumab Ajovy |
|
13.05.02 |
Fumaderm® |
Awaiting Service agreement with CCG |
02.02.02 |
Furosemide |
Tablet 20mg and 40mg, Oral Solution 40mg/5ml, Injection 10mg/ml
|
24.01 |
Furosemide |
Indication
Oedema in heart failure, renal disease and pulmonary oedema
Dose
PO & IV
0.5–1 mg/kg every 12–24 hours, alternatively 0.5–1 mg/kg every 24 hours, if corrected gestational age under 31 weeks.
0.5–1 mg/kg every 8 hours as needed increased if necessary up to 2 mg/kg every 8 hours.
For further information see Y&H ODN formulary - Scroll to top
Administration
See Medusa IV guide for information on administration - Scroll to top
Monitoring
U&E, Ca, Blood sugars, urine output Nephrocalcinosis and nephrolithiasis reported with long-term use of furosemide in preterm infants
Further Info:
IV can be given orally. Caution with liquid preparations and their alcohol content
Supply: Available from pharmacy as stock item |
11.03.01 |
Fusidic Acid |
Eye drops 1%
Alternative to chloramphenicol for empirical treatment in people who:
- Are pregnant.
- Have a personal or family history of blood dyscrasias, such as aplastic anaemia.
- Are intolerant of chloramphenicol.
- Need a twice-a-day treatment for infective conjunctivitis
|
13.10.01.02 |
Fusidic Acid 2% |
Cream and Ointment
High level of resistance in general population due to over use
|
04.07.03 |
Gabapentin |
Capsule (100mg, 300mg and 400mg strengths)
|
04.08.01 |
Gabapentin |
|
04.11 |
Galantamine Reminyl® |
Tablets 8mg, 16mg XL and 24mg XL, Oral liquid 4mg/ml
Second Line for Mild to moderate Alzheimers disease
Usual dose range 16-24mg
Max daily dose 24mg XL
Max sinlge dose 24mg XL |
04.07.04.02 |
Galcanezumab Emgality |
|
05.03.02.02 |
Ganciclovir Cymevene® |
|
11.03.03 |
Ganciclovir 0.15% ophthalmic gel Virgan® |
|
01.01.02 |
Gaviscon |
suspension, 3.1mmol sodium per 5ml |
01.01.02 |
Gaviscon Advance |
suspension, contains 2.3mmol sodium and 1mmol potassium per 5ml. |
01.01.02 |
Gaviscon Infant |
Oral powder, contains 0.92mmol sodium per dose
NOTE: each half dual sachet is identified as one dose. To avoid errors prescribe in terms of 'dose' |
08.01.05 |
Gefitinib Iressa® |
Available via a patient access scheme, please register patients when initiating treatment |
09.02.02.02 |
Gelatin Gelofusine® |
Infusion
500ml and 1 litre bags available
|
09.02.02.02 |
Gelatin Haemaccel® |
|
12.03.01 |
Gelclair® |
Oral gel - sachets |
08.01.03 |
Gemcitabine Gemzar® |
|
07.01.01 |
Gemeprost |
Pessaries 1mg
currently not available |
05.01.04 |
Gentamicin |
|
11.03.01 |
Gentamicin ophthalmic |
Available as:
- Eye drops 0.3%
- Eye drops 0.3% (preservative free - unlicensed)
Specialist use only
|
12.01.01 |
Gentamicin Genticin® |
Drops 0.3% |
24.01 |
Gentamicin |
Indication:
Infection
Dose:
4 mg/kg IV slow bolus
>= 28/40 once daily
<28/40 36hourly
Administration
IV injection over 3-5 minutes or infusion over 30 minutes
Monitoring
Levels before 3rd dose >=28/40
Levels before 2nd dose <28/40
Pre dose levels only (trough).
Levels >2mg/L are considered undesirable, consider modifying dose interval if treatment is to be continued
Levels are not necessary if it is likely gentamicin will be stopped at third dose for negative blood cultures.
It is appropriate to stop blood cultures 36 hours or so after they have been taken, as opposed to when they were recorded as arriving in the lab, if baby was always well.
Further Info:
Gentamicin should be prescribed at 0600, 1200, 1800, 2400 times when being administered on postnatal wards, to minimise risk of maladministration.
Supply:
Available from pharmacy as a stock item. Ensure ONLY the 20mg in 2ml vial is used |
06.01.02.01 |
Gliclazide |
Tablet 40mg and 80mg
Only 80mg tablets stocked at BTHFT
If needed tablets can be crushed and dispersed in water. Liquid can be made specially if required. |
06.01.02.01 |
Gliclazide MR |
MR tablet 30mg
Gliclazide mr/r 30mg approximately equivalent in therapeutic effect to standard formulation gliclazide 80mg
|
06.01.02.01 |
Glimepiride |
Tablets 1mg, 2mg, 3mg and 4mg |
06.01.04 |
Glucagon GlucaGen® HypoKit |
1 unit of glucagon = 1mg of glucagon |
06.01.04 |
GlucoGel® |
|
09.02.02.01 |
Glucose Intravenous |
Available in multiple strengths
Infusion
Dextrose 5% infusion 50ml, 100ml, 250ml, 500ml, 1 litre
Dextrose 10% infusion 500ml
Dextrose 20% infusion 100ml,500ml
Dextrose 50% infusion 500ml
Ampoules
Dextrose 10% 10ml ampoules
dextrose 50% 50ml ampoules |
13.07 |
Glutaraldehyde Glutarol® |
|
01.06.02 |
Glycerol (Glycerin) |
Suppository, available in 1g (infant), 2g (child) and 4g (adult) |
02.06.01 |
Glyceryl Trinitrate |
Available as Tablet (S/L & Buccal), Spray, Patches, Injection.
Injection restricted (secondary care only)- Use Polyethylene (PE), giving set for infusion (NOT PVC!).
|
01.07.04 |
Glyceryl Trinitrate 0.4% Rectogesic® |
Ointment |
07.04.04 |
Glycine |
|
09.08.01 |
Glycine |
- Capsules
- Use by specialist metabolic service only
|
03.01.02 |
Glycopyrronium Seebri breezhaler® |
Inhalation capsule (50micrograms/dose)
for use with Seebri Bteezhaler |
15.01.03 |
Glycopyrronium |
|
01.05.03 |
Golimumab Simponi ® |
To be used as per NICE guidelines:
TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
10.01.03 |
Golimumab Simponi® |
|
13.05.03 |
Golimumab Simponi |
As per NICE guidelines
TA220: Golimumab for the treatment of psoriatic arthritis |
06.05.01 |
Gonadorelin HRF® |
|
06.07.02 |
Goserelin |
Subcut injection (implant) 3.6mg and 10.8mg |
08.03.04.02 |
Goserelin Zoladex® |
|
08.03.04.02 |
Goserelin Zoladex® LA |
|
08.03.04.01 |
Goserelin-Zoladex® |
|
05.02 |
Griseofulvin |
|
13.05.03 |
Guselkumab Tremfya |
To be prescribed as per NICE guidelines for plaque psoriasis:
TA521: Guselkumab for treating moderate to severe plaque psoriasis |
09.08.02 |
Haem Arginate Normasang® |
|
14.04 |
Haemophilus influenzae type B Combined Vaccine Menitorix® |
|
04.02.01 |
Haloperidol |
Tablets 0.5mg, 1.5mg, 5mg, 10mg
Oral solution 10mg/5ml
First generation anitpsychotic
Management of acutely disturbed behaviour
Usual ORAL dose range 1.5mg-5mg upto two to three times daily
Max daily dose 30mg
Max single dose 10mg |
04.02.01 |
Haloperidol |
Injection 5mg/ml (intramuscular)
Management of acutely disturbed behaviour
Usual dose range 2-10mg, then every 4-8hours according to response, Elderly initially half adult dose
Max daily dose 12mg (reduced according BNF June 2014)
Max single dose 2-10mg |
04.02.02 |
Haloperidol Haldol Decanoate® |
Injection (oily) 50mg/ml and 100mg/ml
|
02.08.01 |
Heparin |
Heparin sodium 10 units/ml (for IV line flushes only)
|
02.08.01 |
Heparin |
Heparin sodium 1000 units/1mL.
|
14.04 |
Hepatitis A vaccine |
|
14.04 |
Hepatitis A vaccine Single Component Avaxim® |
|
14.04 |
Hepatitis A vaccine Single Component Vaqta® Paediatric |
|
14.04 |
Hepatitis A vaccine with Hepatitis B vaccine Twinrix® |
|
14.05.02 |
Hepatitis B immunoglobulin |
Obtain direct from LGI Virology Mon-Fri: 08.30-17:00 Tel: 0113-3928750/49 or 3928665
Out of Hours: Seacroft Lodge: 0113-2063283 (ask for Consultant Virologist) |
14.04 |
Hepatitis B vaccine |
|
14.04 |
Hepatitis B vaccine Single Component Engerix B® |
|
14.04 |
Hepatitis B vaccine Single Component HBvaxPRO® |
|
06.01.01.01 |
Humalog® Insulin Lispro |
Rapid acting recombiant human insulin analogue
10mL vial
3mL cartridge for Autopen® Classic or HumaPen®
3mL prefilled Humalog® KwikPen
|
06.01.01.01 |
Humulin R® Insulin 500 units in 1mL |
Insulin 500 units in 1mL
20 ml vial (high strength)
For use by specialist diabetic consultants
|
06.01.01.01 |
Humulin S® Soluble insulin |
Short acting human soluble insulin
10mL vial
3mL cartridge (for most Autopen® Classic or HumaPen®)
|
06.01.01.02 |
Humulin® I Isophane Insulin |
Intermediate/long acting human isophane insulin
10mL vial
3mL cartridge
3mL prefilled KwikPen
|
10.01 |
Hyaluronic acid Hyalgan® |
|
10.03.01 |
Hyaluronidase Hyalase® |
|
02.05.01 |
Hydralazine |
Tablet 25mg, 50mg, Suspension 5mg/5ml |
01.05.02 |
Hydrocortisone Colifoam® |
|
06.03.02 |
Hydrocortisone |
Tablets 10mg and 20mg, Injection 100/ml
if needed tablets can be dispersed in water |
12.03.01 |
Hydrocortisone Corlan® |
Pellets 2.5mg
|
13.04 |
Hydrocortisone |
Cream (0.5% and 1%), Ointment (0.5% and 1%)
Mild
|
13.04 |
Hydrocortisone Hydromol® HC Intensive |
|
13.04 |
Hydrocortisone 1% with Clotrimazole 1% Canesten HC® |
Cream
Mild with antifungal
|
13.04 |
Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort® |
Cream, Ointment
cream stored in the fridge, ointment room temperature
Mild with antifungal
|
13.04 |
Hydrocortisone 1%, Clioquinol 3% Vioform-Hydrocortisone® |
|
13.04 |
Hydrocortisone 1%, Urea 10% and Lactic Acid 5% Calmurid HC® |
|
10.01.02.02 |
Hydrocortisone acetate Hydrocortistab® |
Injection 25mg/ml |
13.04 |
Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H® |
Cream
Mild with antimicrobial
|
12.01.01 |
Hydrocortisone Acetate 1% with Gentamicin 0.3% Gentisone® HC |
Drops
|
13.04 |
Hydrocortisone Butyrate Locoid® |
|
13.11.06 |
Hydrogen Peroxide Crystacide® |
|
13.11.06 |
Hydrogen Peroxide Solution BP |
|
13.02.01 |
Hydromol® |
Cream, Ointment |
13.02.01.01 |
Hydromol® bath and shower |
|
04.07.02 |
Hydromorphone Palladone® |
Capsules m/r |
09.01.02 |
Hydroxocobalamin |
IM Injection
vitamin B12 of choice for therapy - retained in the body longer
|
08.01.05 |
Hydroxycarbamide |
|
08.01.05 |
Hydroxycarbamide Hydrea® |
|
09.01.03 |
Hydroxycarbamide |
|
10.01.03 |
Hydroxychloroquine |
Tablet 200mg
Tablets may be crushed and dispersed in water, liquid (unlicensed special) can be made specially if required.
|
13.05.03 |
Hydroxychloroquine |
Oral medication
SWYAPC shared care guidelines |
11.08.01 |
Hydroxypropyl Guar Systane® |
Eye drops |
03.04.01 |
Hydroxyzine |
Tablets 10mg and 25mg, Liquid 10mg/5ml
Drowsy antihistamine, longer duration of action than chlorphenamine |
01.02 |
Hyoscine Butylbromide Buscopan® |
Tablets 10mg, Injection 20mg/ml
|
04.06 |
Hyoscine Hydrobromide |
|
15.01.03 |
Hyoscine Hydrobromide |
|
11.08.01 |
Hypromellose |
Eye drops 0.3% |
11.08.01 |
Hypromellose Isopto Alkaline® |
Eye drops 1% |
11.08.01 |
Hypromellose Isopto Plain® |
Eye drops 0.5% |
11.08.01 |
Hypromellose Optive Fusion |
Eye drops
For the treatment of severe dry eyes
Only for use by opthalmic department
Replaces use of Optive eye drops |
11.08.01 |
Hypromellose 0.3% with Dextran 70 0.1% Tears naturale® |
Eye drops |
06.01.01.02 |
Hypurin® Bovine Isophane Isophane Insulin |
Intermediate acting bovine insulin
10mL vial
3mL cartridge (fits AutoPen Classic) |
06.01.01.01 |
Hypurin® Bovine Neutral Soluble insulin |
Short acting bovine (highly purified) soluble insulin
10ml vial
3ml cartidges for Autopen® Classic |
06.01.01.01 |
Hypurin® Porcine Neutral Soluble insulin |
Short acting porcine (highly purified) soluble insulin
10ml vial
3ml cartridge for Autopen® classic |
06.01.01.02 |
Hypurin®Bovine Lente Insulin Zinc suspension |
Long acting bovine insulin
10mL vial |
06.06.02 |
Ibandronic Acid Bondronat® |
Tablet 50mg, Infusion 1mg/ml |
06.06.02 |
Ibandronic Acid Bonviva® |
Tablets 150mg, Injection 1mg/ml
Tablet 150mg once MONTHLY dose |
08.01.05 |
Ibrutinib Imbruvica® |
For use in line with NICE TA429
Complete full hepatitis B serology including hepatitis B core antibody status before initiation. If this is positive please refer to Dr Moreea/Dr Southern for advice (see MHRA Drug Safety Update below)
|
10.01.01 |
Ibuprofen |
- Tablet 200mg and 400mg, suspension (100mg/5ml)
|
24.01 |
Ibuprofen |
Indication:
Patent Ductus Arteriosus
Dose:
10 mg/kg loading dose then,
5 mg/kg OD for 2 days
Administration
slow IV bolus or infuse over 15mins
Oral can be considered if IV access is an issue.
Monitoring
Renal function, liver function, platlets and bilirubin
Further Info:
May be diluted in sodium chloride 0.9% or glucose 5% if necessary.
Avoid steroids during course if possible.
Supply:
Available from pharmacy as a stock item.
Double check strength! TWO strengths currently stocked due to manufacturer supply issues. |
08.01.02 |
Idarubicin Hydrochloride Zavedos® |
|
09.08.01 |
Idursulfase Elaprase® |
|
08.01.01 |
Ifosfamide Mitoxana® |
|
02.05.01 |
Iloprost injection |
Injection
Restricted for vascular use |
08.01.05 |
Imatinib Gilvec® |
|
24.01 |
Imipenem |
Indication:
Infection-
Dose:
20 mg/kg dose
< 7days BD
7 - 21 days TDS
21 - 28 days QDS
Dose frequency should be reduced if renal failure suspected and stopped if patient anuric.
Caution in CNS disorders
Administration
IV infusion over at least 30minutes
Dilute to a concentration of 5mg/ml(imipenem) in sodium chloride 0.9% or glucose 5%.
Monitoring
Renal function, hypotension, seizures, myoclonic activity,thrombocytopenia, neurotoxicity(see neonatal formulary)
Further Info:
Also refered to as Imipenem with cilastatin.
Prescribe in terms of Imipenem
Supply:
Available from pharmacy as a named patient.DSU cannot manufacturer. |
04.03.01 |
Imipramine |
Tablets 10mg, 25mg
Usual dose range 75-200mg in divided doses
Max daily dose 200mg (300mg in hospital)
Max single dose 150mg |
13.07 |
Imiquimod Aldara® |
|
24.01 |
Immunisations |
See BNF-C share point document |
14.04 |
Inactivated Influenza Vaccine (Split Virion) |
|
03.01.01.01 |
Indacaterol |
Inhalation pwder, hard capsule with device
150 and 300 microgrammes per inhalation
Specialist initiation |
02.02.01 |
Indapamide |
Tablet 2.5mg, M/R tablets 1.5mg
If needed standard tablets can be dispersed in water for patients with swallowing difficulties or enteral tubes terminating in the stomach. MR tablets should not be crushed. |
05.03.01 |
Indinavir Crixivan® |
|
10.01.01 |
Indometacin |
Tablets 25mg, 50mg |
24.01 |
Indomethacin |
IV NOT available, REVIEW??
Either: 200mcg/kg IV then 100mcg/kg daily for 5 days or 200mcg/kg repeated 12hourly x 3 doses in total Watch for renal and GI side effects. Make 100microgram / ml solution by diluting 1mg in 10ml 0.9% saline, use infusion pump to infuse appropriate dose over 20mins.
|
01.05.03 |
Infliximab Remsima |
Remsima is the brand of choice at BTHFT, Remicade can only be prescribed if approved by DTC.
Remsima is now available as an IV infusion and SC injection. For more information about dosing, contact the pharmacy or gastroenterology teams.
To be used as per NICE guidelines:
TA163: Infliximab for acute exacerbations of ulcerative colitis
TA187: Infliximab and adalimumab for the treatment of Crohn's disease
TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
10.01.03 |
Infliximab Remicade® |
|
13.05.03 |
Infliximab Remsima |
Remsima is brand of choice at BTHFT. Remicade should only be prescribed if approved by DTC.
Remsima is now available as an infusion and SC formulation.
To be prescribed as per NICE guidelines for psoriasis/psoriatic arthritis:
TA134: Infliximab for the treatment of adults with psoriasis
TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
|
14.04 |
Influenza vaccine |
|
24.01 |
Insulin Actrapid |
Indication:
Hyperglycaemia
Dose:
Dose range 0.02-0.1units/kg/hour
Start at 0.05 units/kg/hour
For hyperkalaemia 1 unit is needed for every 30g of glucose.
Administration
IV infusion
5 units of soluble insulin(Actrapid) into 50mls 5%dextrose(0.1units/ml)
See “Insulin – making up and giving” guideline
Monitoring
Blood sugars, potassium, glucosuria and blood gases.
Further Info:
Prime lines and slowly flush with 10mls of infusion to prevent insulin binding to plastic.
Insulin is generally given by a separate intravenous cannula, but when circumstances prevent this an insulin infusion may be connected aseptically to the ’lipid port’.
Supply:
Available from pharmacy as a stock vial. DSU cannot make due to product expiry. |
06.01.01.02 |
Insuman® Basal Isophane Insulin |
Intermediate acting human isophane insulin
5ml vial
3ml cartridge
3ml SoloStar® prefilled pen |
06.01.01.01 |
Insuman® Rapid Soluble insulin |
Short acting human soluble insulin
3mL cartridge for ClikSTAR® and Autopen®
|
08.02.04 |
Interferon Alfa |
|
08.02.04 |
Interferon Alfa Roferon-A® |
|
08.02.04 |
Interferon Alfa Viraferon® |
Initiated by hepatitis specialist team |
07.03.04 |
Intra-uterine Contraceptive Devices Load® 375 |
|
07.03.04 |
Intra-uterine Contraceptive Devices Nova-T® 380 |
|
07.03.02.03 |
Intra-uterine Progestogen Only System Mirena® |
Intra-uterine device
Releases Levonorgesterol 20 micrograms/24hours |
06.02.02 |
Iodine and Iodide |
Aqueous oral solution, total iodine 130mg/ml
Also known as Lugol's iodine
|
03.01.02 |
Ipratropium |
Inhaler CFC-free (20micrograms/dose), Nebuliser solution (250 and 500 micrograms/ml). |
12.02.02 |
Ipratropium Bromide Rinatec® |
Nasal spray 0.03%, ipratropium bromide 21 micrograms/metered spray |
02.05.05.02 |
Irbesartan |
Tablets
If needed tablets can be crushed and dispersed in water. Drug is poorly soluble |
08.01.05 |
Irinotecan Hydrochloride Campto® |
|
09.01.01.02 |
Iron Dextran CosmoFer® |
Ferinject first line
Only use if contraindicated to ferinject |
09.01.01.02 |
Iron Sucrose Venofer® |
Ferinject first line
Venofer is used first line for haemodialysis patients as they are having 100mg doses regularly, hence more cost effective for this indication |
05.02.01 |
Isavuconazole |
- For use by infectious diseases and microbiology team only
|
15.01.02 |
Isoflurane |
|
05.01.09 |
Isoniazid |
|
06.01.01.02 |
Isophane Insulin Hypurin® Porcine Isophane |
|
06.01.01.02 |
Isophane Insulin Insulatard® |
10mL vial
3mL cartridge
InnoLet
|
02.07.01 |
Isoprenaline |
Infusion (secondary care only)
|
02.06.01 |
Isosorbide Dinitrate |
Short acting tablet, spray
Injection- 25mg/50ml ampoule (secondary care only)
Use prepared solution of Isoket 0.05% (25mg/50ml ampoule). Administer by syringe pump. Start at 4ml/hour (2mg/hr). Increase the rate to a maximum of 20ml/hr (10mg/hr) if symptoms persist. decrease the rate if the systolic BP fall below 90mmHG
For additional advice speak to CCU |
02.06.01 |
Isosorbide Mononitrate |
Tablet, MR tablet
Short acting preparations should be prescribed asymmetrically to reduce the risk of nitrate tolerance
If needed tablets can be crushed and dispersed in water. Do not crush MR tablets.
MR is aonce daily, long acting preparation |
13.06.01 |
Isotretinoin Isotrex® gel |
|
13.06.02 |
Isotretinoin Roaccutane® |
Specialist dermatology prescribers only |
01.06.01 |
Ispaghula Husk |
Granules |
05.02 |
Itraconazole Sporanox® |
|
02.06.03 |
Ivabradine |
Tablet 7.5mg and 15mg |
13.06 |
Ivermectin Soolantra® |
Cream
Topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients |
13.10.04 |
Ivermectin |
|
13.05.03 |
Ixekizumab Taltz® |
To be prescribed as per NICE guidelines:
TA442: Ixekizumab for treating moderate to severe plaque psoriasis
TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
|
15.01.01 |
Ketamine injection Ketalar® |
|
13.09 |
Ketoconazole |
Shampoo |
13.10.02 |
Ketoconazole |
|
11.08.02 |
Ketorolac Acular® |
Eye drops 0.5% |
15.01.04.02 |
Ketorolac Toradol® |
|
11.04.02 |
Ketotifen Ketofall® |
- Preservative free eye drop
|
01.06.05 |
Klean-Prep® |
Oral powder
|
02.04 |
Labetalol |
Tablet, (Injection - secondary care only)
If needed tablets can be crushed and dispersed in water. Administer immediately as drug is sensitive to oxidation.
|
04.08.01 |
Lacosamide Vimpat ® |
|
07.02.02 |
Lactic acid Balance Activ Rx® |
Vaginal gel |
01.06.04 |
Lactulose |
Solution
|
05.03.01 |
Lamivudine Zeffix® |
|
04.02.03 |
Lamotrigine |
Tablets 25mg, 50mg, 100mg, 200mg ; dispersible tablets also available
Usual dose range 50-200mg daily with valproate
100mg-400mg daily without valproate
|
04.08.01 |
Lamotrigine |
|
08.03.04.03 |
Lanreotide Somatuline Autogel® |
|
08.03.04.03 |
Lanreotide Somatuline® LA |
|
01.03.05 |
Lansoprazole |
Capsules first line, 15mg and 30mg
Capsules can be opened and beads swallowed without crushing, or can be mixed with food or drink
orodispersible tablets restricted for use in patients with swallowing difficulties or who are on enteral tube feeding. They are also licensed to be given via a NG tube or oral syringe if diluted in 5-10ml water
|
09.05.02.02 |
Lanthanum Fosrenol ® |
Tablet
|
06.01.01.02 |
Lantus® Insulin Glargine |
Intermediate/long acting recombinant human insulin analogue
10mL vial
3mL cartridge for ClikSTAR
3mL disposable prefilled pen - Solostar® |
08.01.05 |
Lapatinib Tyverb® |
Lapatinib with capecitabine - VIA CDF - for locally reccurent or metastatic breast cancer |
09.08.01 |
Laronidase Aldurazyme® |
|
11.06 |
Latanoprost |
Eye drops 0.005%
|
11.06 |
Latanoprost Monopost® |
Eye drops 0.005% Preservative free
Single dose 30x0.2ml
Only for use in ophthalmics as a second line agent to standard latanoprost (preserved) where the patient has developed an allergy/intolerance to the preservative. Please also note that Saflutan (Tafluprost) (single dose/preserbvative free) will cease to be used.
|
11.06 |
Latanoprost 0.005% with timolol 0.5% Fixapost® |
- Preservative free 0.2ml unit dose eye drop
- Opthalmology only
- To be used if patient reacts to preservative containing drops (latanoprost/timolol)
|
11.06 |
Latanoprost 0.005% with Timolol 0.5% Xalacom® |
Eye drops |
10.01.03 |
Leflunomide |
|
08.02.04 |
Lenalidomide |
|
08.03.04.01 |
Letrozole |
|
08.03.04.02 |
Leuprorelin Acetate Prostap® SR |
|
08.03.04.02 |
Leuprorelin Acetate Prostap® 3 |
|
06.01.01.02 |
Levemir® Insulin Detemir |
Long acting recombinant human insulin analogue
3mL cartridge for NovoPen® devices
3mL prefilled FlexPen® |
04.08.01 |
Levetiracetam |
|
11.06 |
Levobunolol |
Eye drops 0.5% |
15.02 |
Levobupivacaine Chirocaine® |
|
04.09.01 |
Levodopa |
|
05.01.12 |
Levofloxacin |
|
11.03.01 |
Levofloxacin |
|
04.02.01 |
Levomepromazine Nozinan® |
|
07.03.05 |
Levonogrestrel Levonelle® 1500 |
Tablet 1.5mg
Single dose as soon as possible after coitus preferbaly within 12 hours but no later than after 72 hours (3 days. May be used between 72 and 96 hours but efficacy decreases with time.
|
06.02.01 |
Levothyroxine |
Tablets 25mcg, 50mcg,100mcg
Liquid 25mcg/5ml, 50mcg/ml, 100mcg/5ml - significantly more expensive than tablets, only use where necessary
If needed tablets can be crushed and dispersed in water |
02.03.02 |
Lidocaine |
Injection, Minijet(disposable syringe) |
15.02 |
Lidocaine Versatis® |
Medicated plasters 5%
Restricted for pain management service recommendation only
Apply for 12 hours followed by a 12 hour plaster-free period
Discontinue if no repsonse after 4 weeks |
15.02 |
Lidocaine 2.5% with Prilocaine 2.5% EMLA® |
|
15.02 |
Lidocaine2% with Chlorhexidine 0.25% Instillagel® |
|
15.02 |
Lignocaine |
|
01.06.07 |
Linaclotide Constella® |
|
06.01.02.03 |
Linagliptin Trajenta® |
Tablet 5mg
First choice DPP4 inhibitor at BTHFT |
05.01.07 |
Linezolid |
|
06.02.01 |
Liothyronine |
Available as tablets or injection
Tablets. For specialist initiation. Discuss with endocrinologist before initiation. Similar action to levothyroxine but is ore rapidly metabolised and has more rapid effect. 20-25 microgrames is equivalent to 100 micrograms of levothyroxine
Injection also known as triiodothyronine
|
11.08.01 |
Liquid Paraffin Lacri-Lube® |
Eye ointment
- Prescribe Xailin night (same formulation more cost effective)
|
11.08.01 |
Liquid Paraffin Xailin Night® |
Eye ointment |
06.01.02.03 |
Liraglutide Victoza® |
injection 6mg/ml |
02.05.05.01 |
Lisinopril |
Tablets, Oral solution
If needed tablets can be dispersed in water
Oral solution, for genuine swallowing difficulties or NG tubes
|
04.02.03 |
Lithium Carbonate Camcolit® |
Tablets 250mg (Li 6.8 mmol), 400mg (Li 10.8mmol)
Prescribe by brand
Usual dose range 400-1200mg daily
Max daily dose is adjustable
|
04.02.03 |
Lithium Carbonate Priadel® |
Tablets 250mg(Li 5.4mmol), 400mg (Li 10.8mmol)
Prescribe by brand
Usual dose range 400-1200mg daily
Max daily dose is adjustable
|
04.02.03 |
Lithium Citrate Li-Liquid® |
|
04.02.03 |
Lithium Citrate Priadel® |
Liquid (priadel) 520mg/5ml (Li 5.4mmol/5ml)
Prescribe by brand
Usual dose range 400-1200mg daily ; 5mls = 200mg lithium carbonate
|
11.04.02 |
Lodoxamide Alomide® |
Eye drops 0.1% |
04.03.01 |
Lofepramine |
Tablets 70mg |
08.01.01 |
Lomustine |
|
01.04.02 |
Loperamide |
Capsule 2mg, Tablets 2mg, Syrup (1mg/5ml) |
03.04.01 |
Loratadine |
Liquid 5mg/5ml
Tablets not stocked, use desloratidine |
04.01.02 |
Lorazepam |
Tablet 1mg, 2.5mg
Usual dose range: 1 to 4mgdaily in divided doses
Max daily dose 4mg
Max single dose 2mg |
04.01.02 |
Lorazepam injection |
injection 4mg/ml
Usual dose range: 1 to 4mg daily in divided doses
Max daily dose 4mg
|
15.01.04.01 |
Lorazepam |
|
02.05.05.02 |
Losartan |
Tablets
1st line choice ARB if patients haven't tolerated an ACE inhibitor
Licensed for Renal protection in type 2 diabetic patients with nephropathy (macroalbuminuria) (unlike candesartan)
If needed tablets can be crushed and dispersed in water |
11.04.01 |
Loteprednol Lotemax® |
Eye drops 0.5% |
01.06.07 |
Lubiprostone Amitiza® |
Capsules 24micrograms
Only to be prescribed by Gastro/Colorectal consultants
Treatment of chronic idiopathic constipation as per NICE criteria
Adult over 18 years, 24 micrograms twice daily for 2 weeks
|
13.06.02 |
Lymecycline Tetralysal®300 |
Capsules 408mg |
01.06.04 |
Macrogol Movicol® |
Sachets
|
01.06.04 |
Macrogol Movicol®- Half |
Sachets |
09.05.01.03 |
Magnesium Glycerophosphate |
Tablet (unlicensed)
Contains 4mmol magnesium per tablet
Tablets can be crushed and dispersed in water.
|
09.05.01.03 |
Magnesium Sulphate |
|
24.01 |
Magnesium Sulphate |
Indication:
Hypomagnesemia, PPHN
Dose:
For low magnesium (usually <0.5mmol/l) 100mg/kg bd IM or oral usually x 2 doses
For PPHN loading dose 250mg/kg over 10 mins then 20-75 mg/kg/hour IV infusion
Administration
4ml of magnesium sulphate 50%(2g or 8.2mmol) made up to 40 mls with glucose 10%.(50mg/ml)
Monitoring
High doses often produce hypotonia, respiratory depression, systemic as well as pulmonary vasodilation.
Further Info:
Supply:
Available from pharmacy as ward stock. Magnesium Sulphate 50% comes as a 2ml or 10ml ampoule |
13.10.05 |
Magnesium Sulphate Paste BP |
|
01.01.01 |
Magnesium Trisilicate Mixture BP |
Suspension, 6mmol sodium/10ml |
01.06.04 |
Magrogol Movicol® Paediatric |
Sachets |
02.02.05 |
Mannitol |
IV infusion
|
05.03.01 |
Maraviroc |
|
14.04 |
Measles, Mumps and Rubella Vaccine, Live (MMR) |
|
01.02 |
Mebeverine Hydrochloride |
135mg Tablet
200mg MR Tablet non-formulary
Oral suspension also available (50mg/5ml) but significantly more expensive |
01.02 |
Mebeverine Hydrochloride Colofac® MR |
Use mebeverine 135mg tablets |
06.04.01.02 |
Medroxyprogesterone Acetate |
Tablet 5mg and 10mg |
07.03.02.02 |
Medroxyprogesterone Acetate Depo-Provera® |
Injection 150mg/ml |
08.03.02 |
Medroxyprogesterone Acetate Provera® |
|
10.01.01 |
Mefenamic Acid |
Capsules 250mg, Tablets 500mg |
08.03.02 |
Megestrol Acetate Megace® |
|
04.01.01 |
Melatonin |
|
08.01.01 |
Melphalan |
|
04.11 |
Memantine Ebixa® |
Tablets 10mg and 20mg
First Line for Moderate to Severe Alzheimers disease
Usual dose range 10-20mg
Max daily dose 20mg
Max single dose 20mg |
09.06.06 |
Menadiol Sodium Phosphate |
|
14.04 |
Meningococcal group C conjugate vaccine |
|
15.02 |
Mepivacaine Scandonest Plain® |
|
03.04.02 |
Mepolizumab Nucala® |
Initiation by specialist respiratory consultant for severe refractory eosinophilic asthma in adults only |
04.07.02 |
Meptazinol Meptid® |
|
09.08.01 |
Mercaptamine Cystagon® |
|
01.05.03 |
Mercaptopurine |
Tablets 50mg
|
08.01.03 |
Mercaptopurine |
|
05.01.02.02 |
Meropenem |
|
24.01 |
Meropenem |
Indication:
Infection
Dose:
<7days 40mg/kg 12 hourly
>7days 40mg/kg 8 hourly
>1 month 40mg/kg 8 hourly
If renal failure of any severity is suspected, reduce dose and interval, see below:
Mild (eGFR 26-50ml/min) 20mg/kg 12hourly
Moderate (eGFR 10-25ml/min) 10mg/kg 12hourly
Severe (eGFR <10ml/min) 10mg/kg 24houly
Administration
Dilute to 10mg/ml (using displacemnt values) in glucose 5% or sodium chloride 0.9%.
IV infusion over 15-30minutes
Monitoring
Review renal function before prescribing and review daily:
Further Info:
Supply:
Available from pharmacy as stock. DSU can supply named patient syringes. |
01.05.01 |
Mesalazine Octasa® |
|
01.05.01 |
Mesalazine Mezavant® XL |
Tablets m/r, 1.2g
Once daily dosing |
01.05.01 |
Mesalazine Pentasa® |
Available as:
- 500mg, 1g modified-release tablets
- 1g, 2g, 4g modified-release granules sachets
- 1g rectal suppositories
- 1g/100ml enema
|
01.05.01 |
Mesalazine Salofalk® |
Granules 500mg, Enema 2g
Salofalk tablets not stocked at BTHFT, use Octasa or Pentasa |
08.01 |
Mesna |
|
02.07.02 |
Metaraminol |
Injection (secondary care only)
|
06.01.02.02 |
Metformin |
Tablet 500mg, 850mg, Tablet MR 500mg, 750mg, 1000mg (for patients with proven GI intolerance), Oral powder 500mg, 1000mg
If needed tablets may be crushed and dispersed in water or a powder formulation is now available. |
04.07.02 |
Methadone |
Tablet, Liquid
For initiation by pain team only when used as an analgesic
|
04.10.03 |
Methadone |
Liquid 1mg/ml sugar free
Substance misuse
Usual dose range 30-120mg
Always confirm with patients substance misuse service or regular community pharmacy to confirm the dose before prescribing. Contact details for Bradford Substance Misuse:
Bradford Substance Misuse Directory
|
01.05.03 |
Methotrexate |
Tablets 2.5mg
2.5mg tablets preferred
Cytotoxic, DO NOT crush and disperse in water
|
08.01.03 |
Methotrexate |
|
10.01.03 |
Methotrexate |
|
10.01.03 |
Methotrexate Metoject® |
|
13.05.03 |
Methotrexate |
Oral medication - prescibed as 2.5mg tablets
Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing
SWYAPC shared care guidelines |
02.05.02 |
Methyldopa |
Tablet
Should only be used for hypertension when other agents have failed or aren't suitable.
If needed tablets can be crushed and dispersed in water. Crush thoroughly and flush tube well to prevent blockage.
|
01.06.06 |
Methylnaltrexone Relistor® |
Vials
Restricted for management of intractable opioid induced constipation in patients not responding to usual laxative treatment - Palliative care teams only |
04.04 |
Methylphenidate |
Tablets
Drug treatment of attention deficit hyperactivity disorder (ADHD)
Concerta XL
Usual dose range 18mg - 54mg
Max daily dose 108mg
Equasym XL
usual dose range 10mg-60mg
Max daily dose 90mg (unlicensed)
Medikinet XL
Usual dose range 10mg-60mg
Max daily dose 90mg (unlicensed)
|
06.03.02 |
Methylprednisolone |
Tablets 2mg, 4mg 16mg and 100mg
Injection (solu-medrone) 40mg, 125mg, 500mg and 1g vial
Intramuscular depot 40mg/ml |
10.01.02.02 |
Methylprednisolone Acetate Depo-Medrone® |
Injection 40mg in 1mL
Injection 80mg in 2mL
|
04.06 |
Metoclopramide |
Tablet, Liquid, Injection
Not recommended for patients under 20 years of age due to risk of dystonic reactions
Metoclopramide should only be prescribed for short-term use (up to 5 days).
For adults, the maximum dose in 24 hours is 30 mg (or 0.5 mg per kg bodyweight).
Can be given S/C (unlicenced but accepted practice)
|
02.02.01 |
Metolazone |
Tablet
unlicensed
Position statement: Can be used in combination with a loop diretic in severe heart failure. Initiation of the drug should occur after consultation with the Cardiology team. Close monitoring of renal function is required |
02.04 |
Metoprolol |
Tablet, MR tablet,(Injection - secondary care only)
Heart failure- third line, where there is a perceived need to use a short acting cardioselective beta-blocker.
If needed tablets can be crushed and dispersed in water. Do not crush/disperse MR tablets.
|
05.01.11 |
Metronidazole |
|
05.04.03 |
Metronidazole |
|
07.02.02 |
Metronidazole Zidoval® |
Vaginal gel 0.75%
40g pack with 5 applicators |
13.10.01.02 |
Metronidazole |
|
24.01 |
Metronidazole |
Review dosing? BNFC?
Indication:
Anaerobic bacterial infection
Dose:
15 mg/kg loading dose then:
7.5 mg/kg 12hourly(<28 days old)
7.5 mg/kg 8hourly(>28days old)
Administration
IV infusion over at least 15 minutes
Monitoring
Liver function, FBC,
Further Info:
Dose may need adjusting if baby on steroids or barbituates
Supply:
Available from pharmacy as stock. |
13.10.01.02 |
Metronidazole 0.75% |
|
06.07.03 |
Metyrapone Metopirone® |
|
07.02.02 |
Miconazole Gyno-Daktarin® |
Intravaginal Cream 2% |
12.03.02 |
Miconazole Daktarin® |
Oral Gel |
13.10.02 |
Miconazole |
|
04.08.02 |
Midazolam |
|
15.01.04.01 |
Midazolam |
Injection 5mg/ml, 10mg/5ml
Management of disturbed behaviour
Max daily dose 2.5mg-7.5mg (15mg in 24 hours)
Max single dose 7.5mg
|
24.01 |
Midazolam |
Indication:
Seizures, sedation
Dose:
May require a loading dose
60-150micrograms/kg/hour continous infusion
Administration
10mg of midazolam into 50mls glucose 5%or 10% for continous infusion
Monitoring
Heart rate, hypotension, hypotonia, agitation, urine output, temp and .
Further Info:
Can accumulate in neonates, consider reducing dose after 24hours if continuious infusion likely to continue.
Antidote: See Flumazenil
Supply:
Available from pharmacy as stock. DSU can make syringes on request. Controlled drug. |
20 |
MIDAZOLAM buccal |
|
02.07.02 |
MIDODRINE Tablets 2.5 mg, 5mg |
|
07.01.02 |
Mifepristone Mifegyne® |
Tablet 200mg |
05.01.03 |
Minocycline |
|
05.01.03 |
Minocycline Minocin® MR |
|
07.04.02 |
Mirabegron Betmiga® |
Capsule 25mg and 50mg |
04.03.04 |
Mirtazapine |
Tablets 15mg, 30mg and 45mg
Orodispersible tablets also avaialable |
01.03.04 |
Misoprostol Cytotec® |
Tablet 200 micrograms
Not first line for gastro protection |
07.01.01 |
Misoprostol |
Tablets
|
08.01.02 |
Mitomycin |
|
11.99.99.99 |
Mitomycin C |
Intravitreal Injection
Unlicensed - prepared by aseptic unit
|
08.01.02 |
Mitoxantrone Onkotrone® |
|
08.01.02 |
Mitoxantrone (Mitozantrone) |
|
15.01.05 |
Mivacurium Chloride |
|
04.03.02 |
Moclobemide |
Tablets 150mg and 300mg
Usual dose range 150-600mg
Max daily dose 600mg
Max single dose 300mg |
04.04 |
Modafinil Provigil® |
|
12.02.01 |
Mometasone Furoate Nasonex® |
Nasal spray 50micrograms per spray
|
13.04 |
Mometasone Furoate 0.1% Elocon® |
Cream, Ointment, Scalp lotion
Potent
|
03.03.02 |
Montelukast Singulair® |
Tablet 10mg, Chewable tablet 5mg, Granules 4mg
|
04.07.02 |
Morphine |
Normal relase (~4 hours effect): Oral solution (e.g. Oramorph®), Tablet (Sevredol®)
- Slow release (~12hr effect): Morphgesic Tablet MR 10mg, 30mg, 60mg, 100mg, 200mg, (MST® Tablet MR 5mg and 15mg ONLY), Injection.
First line strong opioid
|
24.01 |
Morphine Sulphate |
Indication:
Sedation, analgesia
Dose:
20 microcrams/kg/hr
Dose range of 5 - 20 microcrams/kg/hr is normally prescribed
Administration
IV infusion
Standard stock syringes are 2.5mg in 50mls glucose 5% (50micrograms/ml)
Monitoring
Respiratory rate, blood pressure,temperature and agitation.
Further Info:
Prescribe concentration, rate and dose
Antidote: See Naloxone
Compatibility: Glucose 5%, Glucose 10%, Sodium chloride 0.9%,Adrenaline, Aminophylline, Amiodarone, Calcium chloride, Dobutamine, Fentanyl, Insulin, Magnesium sulphate, Midazolam, Potassium chloride
Supply:
Available from DSU as a stock syringe. Order every Tuesday. 1mg in 50ml diluent is also available on named requests. |
24.01 |
Morphine Sulphate Neonatal Abstinence Syndrome |
Indication:
Neonatal Abstinence Syndrome
Dose:
Start: 40 micrograms/kg/dose 4 hourly review daily
Reduce as soon as tolerable to:
30 micrograms/kg/dose 4 hourly then
20 micrograms/kg/dose 4 hourly then
10 micrograms/kg/dose 4 hourly then stop.
Discuss sedative use with consultant before starting.
Administration
Oral solution(100micorgrams in 1ml)
Monitoring
Respiratory rate, blood pressure,temperature and agitation.
Further Info:
Supply:
Available from DSU as a stock item. M2(TCU) hold stock for OOH use. |
01.06.05 |
Moviprep® |
Oral powder sachets
Restricted to use as a bowel prep prior to colonoscopy |
05.01.12 |
Moxifloxacin |
For frug resistant Tuberculosis, seek advice from infectious diseases |
05.01.12 |
Moxifloxacin |
|
02.05.02 |
Moxonidine |
Tablet
Restricted for resistant or refractory cases
If needed tablets can be crushed and dispersed in 50ml water. Crush thoroughly and disperse well before administering to prevent tube blockage.
|
09.06.07 |
Multivitamin |
|
09.06.07 |
Multivitamin preparations Dalivit® |
|
09.06.07 |
Multivitamin preparations Abidec® |
|
13.10.01.01 |
Mupirocin |
Ointment and Cream |
08.02.01 |
Mycophenolate Mofetil CellCept® |
|
08.02.01 |
Mycophenolate Sodium Myfortic® |
|
02.06.04 |
Naftidrofuryl Oxalate |
|
15.01.07 |
Naloxone |
|
18 |
Naloxone |
|
04.10.03 |
Naltrexone |
|
10.01.01 |
Naproxen |
|
12.02.03 |
Naseptin® Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% |
Cream
- Should not be used in patients with a peanut allergy
- MRSA suppression: Four times daily for 10 days
|
08.02.04 |
Natalizumab Tysabri® |
|
02.04 |
Nebivolol Nebilet® |
Tablet
Specialist initiation only
Tablets can be crushed and mixed with water for administration |
11.04.02 |
Neodocromil Rapitil® |
Eye drops 2% |
10.02.01 |
Neostigmine |
|
15.01.06 |
Neostigmine |
|
15.01.06 |
Neostigmine with Glycopyrronium |
|
02.06.03 |
Nicorandil |
Tablet 10mg and 20mg
If needed tablets can be crushed and dispersed in water |
04.10 |
Nicotine Nicotinell® |
|
04.10.02 |
Nicotine |
|
02.06.02 |
Nifedipine |
Tablets, MR tablets, capsules, MR capsules
Prescribe by brand according to medicines policy |
08.01.05 |
Nilotinib Tasigna® |
|
02.06.02 |
Nimodipine Nimotop® |
Tablet
Injection- use Polyethylene (PE) giving set for infusion (NOT PVC!)
Specialist use in secondary care only
If needed tablets can be crushed and dispersed in water. Give immediately as rapid degradation occurs. |
04.01.01 |
Nitrazepam |
Tablets 5mg, suspension 2.5mg/5ml
Usual dose range: 5-10mg at night
Max daily dose 10mg
Max single dose 10mg |
05.01.13 |
Nitrofurantoin |
|
15.01.02 |
Nitrous oxide |
|
08.01 |
Nivolumab Opdivo® |
For use in line with NICE TA384, TA400 & TA417 |
02.07.02 |
Noradrenaline / Norepinephrine |
Injection (secondary care only)
|
06.04.01.02 |
Norethisterone |
Tablet 5mg |
08.03.02 |
Norethisterone |
|
14.05.01 |
Normal immunoglobulin for Intramuscular use |
|
14.05.01 |
Normal immunoglobulin for Intravenous use |
|
14.05.01 |
Normal immunoglobulin for Subcutaneous use |
|
04.03.01 |
Nortriptyline |
|
06.01.01.01 |
NovoRapid® Insulin Aspart |
Rapid acting recombinant human insulin analogue
10mL vial
3mL Penfill® cartridge for NovoPen® devices
3mL prefilled Flexpen®
3ml prefilled FlexTouch® pen
|
A2.05.02 |
Nutilis® Powder |
- For adult renal patients or patients on a sodium restricted diet
- Contact the speach and language therapists (SALT) team for futher information and advice
|
13.04 |
Nystaform-HC® |
Cream, Ointment
Mild with antimicrobial
Cream contains 0.5% hydrocortisone, Ointment contain 1%
useful for facial eczema in children
|
12.03.02 |
Nystatin Nystan® |
Oral suspension 100 000 units per mL
|
13.10.02 |
Nystatin |
|
24.01 |
Nystatin |
Indication:
Prophylaxis for ventilated babies < 1500g with central lines.
Treatment of oral and perioral fungal infections
Dose:
Prophylaxis: 50,000units TDS
Treatment: 100,000units QDS usually for 7 days, and continued for 48 hours after lesions have healed.
Administration
Oral
Monitoring
Further Info:
Document on drug chart indication(Prophylaxis or treatment)
If bottle or breast fed administer after feed.
Consider treament for breast feeding mums.
Supply:
Available from pharmacy as a stock item.(100,000units in 1ml) |
13.10.02 |
Nystatin 100,000 uints/g Nystan® |
|
13.10.02 |
Nystatin with Chlorhexidine cream Nystaform® |
|
01.09.01 |
Obeticholic acid Ocaliva® |
Restricted for treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. |
11.08.02 |
Ocriplasmin Jetrea® |
|
13.11 |
Octenisan® |
Skin antisepsis
- For patients requiring prolonged use or recurrent applications (due to multiple admissions), those with sensitive skin or immobile bedbound patients
- MRSA suppression: use once daily for duration of admission
|
08.03.04.03 |
Octreotide Sandostatin® |
|
08.03.04.03 |
Octreotide Sandostatin Lar® |
|
06.04.01.01 |
Oestrogen only HRT gel Oestrogel® |
|
06.04.01.01 |
Oestrogen only HRT patch Estradot®, Evorel® |
|
06.04.01.01 |
Oestrogen only HRT tablet Elleste-Solo®, Premarin® |
|
06.04.01.01 |
Oestrogens for HRT Elleste-Solo® MX |
|
07.02.01 |
Oestrogens, Topical Gynest® |
Intravaginal cream: estriol 0.01% (10x weaker than Ovestin)
|
07.02.01 |
Oestrogens, Topical Ovestin® |
Intravaginal cream: estriol 0.1% (10x stronger than Gynest)
|
07.02.01 |
Oestrogens, Topical Vagifem® |
Vaginal tablet: estradiol 10mcg
25 mcg strength was discontinued end 2012. 10mcg considered as efficacious
|
08.02.03 |
Ofatumumab Arzerra® |
|
05.01.12 |
Ofloxacin |
|
11.03.01 |
Ofloxacin Eye drops Exocin® |
eye drops 0.3% |
13.02.01 |
Oilatum® |
Cream, Shower gel, emmolient bath oil |
13.02.01.01 |
Oilatum® Plus emollient bath additive |
|
01.07.03 |
Oily phenol injection BP |
Injection |
04.02.01 |
Olanzapine Zyprexa® |
Tablets 2.5mg, 5mg, 10mg, 15mg, 20mg ; dispersible tablets also available (significantly more expensive)
second generation antipsychotic
Usual dose range 5-20mg daily
Max daily dose 20mg
Max single dose 20mg |
04.02.02 |
Olanzapine Embonate ZypAdhera® |
|
12.01.03 |
Olive Oil Ear Drops |
Drops |
03.04.02 |
Omalizumab Xolair® |
Specialist use only |
13.05.03 |
Omalizumab Xolair |
As per NICE guidelines:
TA339: Omalizumab for previously treated chronic spontaneous urticaria |
02.12 |
Omega-3-Acid Ethyl Esters Omacor® |
|
01.03.05 |
Omeprazole |
Capsules first line 10mg, 20mg and 40mg
Capsules can be opened and beads swallowed without crushing, or can be mixed with food or drink
orodispersible tablets restricted for use in patients with swallowing difficulties or who are on enteral tube feeding and first choice lansoprazole is not suitable
|
01.03.05 |
Omeprazole IV |
Restricted as per guideline - See Upper GI Bleeds Clinical Pathway (below) |
04.06 |
Ondansetron |
Tablets, injection, syrup and orodispersible film. |
04.09.01 |
Opicapone Ongentys® |
2nd line where entacapone not appropriate, tolerated or effective or in those with mild-moderate liver impairment |
07.03.02.01 |
Oral Progestogen Only Contraceptives Cerazette®, Zelleta® |
Prescribe by brand, Zelleta® preferred brand at BTHFT
|
07.03.02.01 |
Oral Progestogen Only Contraceptives Micronor® |
|
07.03.02.01 |
Oral Progestogen Only Contraceptives Norgeston® |
|
07.03.02 |
Oral Progestogen-Only Contraceptives Femulen® |
Tablet, etynodiol diacetate 500 micrograms |
07.03.02 |
Oral Progestogen-Only Contraceptives Norgeston® |
|
07.03.02 |
Oral Progestogen-Only Contraceptives Cerazette® |
|
07.03.02 |
Oral Progestogen-Only Contraceptives Micronor® |
Tablet, norethisterone 350 micrograms |
09.02.01.02 |
Oral Rehydration Salts Dioralyte® |
oral powder |
08.01.05 |
Oxaliplatin |
|
11.07 |
Oxybuprocaine Hydrochloride Minims® |
|
07.04.02 |
Oxybutynin |
Tablet 2.5mg and 5mg
Modified release 5mg and 10mg
|
07.04.02 |
Oxybutynin Hydrochloride Kentera® |
Patch 36mg (releasing approx 3.9mg/24 hours)
Change patch twice weekly (every 3-4 days) |
04.07.02 |
Oxycodone |
Normal release: Capsule (OxyNorm), Liquid, Concentrate liquid, Injection
Slow release: Tablet (OxyContin)
Not first line strong opioid
More expensive, and not superior to morphine. Only for patients unable to tolerate idiosyncratic side effects with morphine.
Always give prophylactic laxatives
|
05.01.03 |
Oxytetracycline |
|
13.06.02 |
Oxytetracycline |
Tablets 250mg |
07.01.01 |
Oxytocin Syntocinon® |
Injection 5units/ml |
08.01.05 |
Paclitaxel Abraxane® |
NAB-Paclitaxel- Normal Albumin Bound – Paclitaxel .
Dosing NOT interchangeable with “normal” paclitaxel
Used in Combination with Gemcitabine for Pancreatic Cancer – VIA CDF
Approved for Breast Cancer
|
08.01.05 |
Paclitaxel |
|
04.02.02 |
Paliperidone Xeplion® |
|
05.03.05 |
Palivizumab Synagis® |
|
04.06 |
Palonosetron with netupitant Akynzeo® |
- Palonosetron 0.5mg with netupitant 300mg
- For use by oncology team only
- Anti-emetic for use with cancer chemotherapy
|
04.06 |
Palonosetron with netupitant Akynzeo® |
- Palonosetron 0.5mg with netupitant 300mg
- For use by oncology team only
- Anti-emetic for use with cancer chemotherapy
|
01.09.04 |
Pancreatin Creon® Micro |
Granules
Only for paediatrics
All pancreatin products contain pancreatin from a porcine source, currently an alternative is not available. |
01.09.04 |
Pancreatin Creon® 10000, 25000, 40000 |
Capsule
All pancreatin products contain pancreatin from a porcine source, currently an alternative is not available. |
24.01 |
Pancuronium |
Indication:
Muscle relaxation
Dose:
100-200 micrograms/kg/dose PRN
Administration
IV bolus over 30seconds
Dilute 1ml to 10ml with sodium chloride 0.9% or glucose 5% (200micrograms in 1ml)
Monitoring
Blood pressure, ventilation requiremnts may increase.
Further Info:
Longer acting than atracurium
Antidote: See Neonatal Formulary 6th Ed
Supply:
Available from pharmacy as stock (2000 micrograms in 1ml) |
15.01.05 |
Pancuronium Bromide |
|
08.01.05 |
Panitumumab |
For use in line with NICE TA439
Patient Access Scheme available for this treatment (in line with NICE TA439) |
01.03.05 |
Pantoprazole |
Tablets, 20mg and 40mg |
01.03.05 |
Pantoprazole IV |
Restricted as per guideline - See Upper GI Bleeds Clinical Pathway (below) |
04.07.01 |
Paracetamol Perfalgan® |
|
04.07.01 |
Paracetamol |
Tablet, Soluble tablet, Injection, Liquid, Suppositories
The dose of IV paracetamol should be reduced in patients weighing less than 50Kg, the dose should be calculated as 15mg/kg four times a day.
The maximum daily infusion dose should be 3g in patients greater than 50 kg body-weight who have risk factors for hepatotoxicity such as: alcohol dependence; hepatocellular insufficiency, chronic alcoholism, chronic malnutrition, or dehydration.
|
24.01 |
Paracetamol |
Indication:
Analgesia for mild to moderate pain.
Dose:
IV
Preterm: >32/40 7.5mg/kg every 8hours(Max 25mg/kg in 24hours)
Term: 10mg/kg every 4-6 hours(Max 30mg/kg in 24hours)
Oral
Preterm 28-32/40 10-15mg/kg every 8 to 12 hours(Max 30mg/kg in 24hours)
Preterm >32/40 10-15mg/kg every 6 to 8 hours(Max 60mg/kg in 24hours)
Indicate maximum daily dose in 24hours on chart
Administration
IV infusion over 15minutes
Monitoring
Blood pressure,heart rate(tachycardia),Liver Function,
Renal function
Further Info:
Give undiluted or dilute to a concentration of not less than 1 mg/mL in Glucose 5% or Sodium Chloride 0.9%; use within 30minutes of dilution
Supply:
Available from pharmacy as a name pateint request.
Supplied as 500mg in 50ml vial (10mg/ml) |
04.07.01 |
Paracetamol and codeine Co-codamol® 8/500 |
Tablet, Soluble tablet.
|
04.07.01 |
Paracetamol and codeine Co-codamol® 30/500 |
Tablet, Effervescent tablet |
15.01.04.02 |
Parecoxib Dynastat® |
|
24.03 |
Parenteral Nutrition |
See current sharepoint protocol |
09.06.04 |
Paricalcitol |
|
04.03.03 |
Paroxetine |
Tablets 10mg, 20mg and 30mg
Usual dose range 20-50mg daily
Max daily dose 50mg
Max single dose 50mg |
09.02.01.01 |
Patiromer sorbitex calcium Veltassa® |
- 8.4g and 16.8g sachets
- For treatment of acute and chronic hyperkalaemia
|
14.04 |
Pediacel® |
|
08.02.04 |
Peginterferon Alfa Pegasys® |
Initiated by hepatitis specialist team |
08.02.03 |
Pembrolizumab KeyTruda® |
For use in line with NICE TA357, NICE TA366, NICE TA428 & TA447 |
08.01.03 |
Pemetrexed Alimta® |
Maintenance pemetrexed available through the CDF |
09.08.01 |
Penicillamine |
|
10.01.03 |
Penicillamine |
|
08.01.05 |
Pentostatin Nipent® |
|
01.02 |
Peppermint Oil |
Colpermin®
Colpermin brand contains arachis (peanut) oil
Peppermint oil 0.2ml
Capsule, MR, EC
Mintec®
Peppermint oil 0.2ml
Capsule, EC |
01.02 |
Peppermint water |
Solution unlicensed |
04.08.01 |
Perampanel Fycompa® |
- For initiation by consultant neurologist only
|
13.10.04 |
Permethrin 1% Lyclear® Creme Rinse |
|
13.10.04 |
Permethrin 5% |
Dermal Cream |
08.01.05 |
Pertuzumab Perjeta® |
1st line treatment of locally advanced or metastatic breast cancer |
04.07.02 |
Pethidine |
Tablet, Injection
preferred in obstetrics |
04.03.02 |
Phenelzine |
Tablets 15mg
Usual dose range :aim for lowest possible maintenace dose
Max daily dose 90mg
Max single dose 30mg |
02.08.02 |
Phenindione |
Tablet
For patients intolerant of warfarin
|
04.08.01 |
Phenobarbital |
|
04.08.02 |
Phenobarbital |
|
24.01 |
Phenobarbital Phenobarbitone |
Indication:
Seizures
Dose:
20 mg/kg loading dose
5 mg/kg/day maintenance
Administration
IV over at least 20minutes(no faster than 1mg/kg/minute)
Take 1ml of 200mg/ml and dilute to 10ml with water for injection(20mg in 1ml)
Monitoring
Blood pressure(Hypotension, respiratory rate
Blood Levels 20 - 40mg/l
Further Info:
Supply:
Available from pharmacy as stock (200mg in 1ml) |
02.05.04 |
Phenoxybenzamine Hydrochloride |
Capsules
Specialist use only for hypertensive episodes in phaeochromocytoma
|
05.01.01.01 |
Phenoxymethylpenicillin |
|
A2.07 |
Phenylalanine Amino Acid Supplement |
|
02.07.02 |
Phenylephrine |
Injection not stocked within BTHFT |
11.05 |
Phenylephrine Hydrochloride |
Minims®Phenylephrine Hydrochloride 2.5% and 10% single use eye drops |
04.08.01 |
Phenytoin |
|
04.08.01 |
Phenytoin Epanutin® |
|
24.01 |
Phenytoin |
Indication:
Seizures
Dose:
IV
Loading dose 15 mg/kg
Maintenance 2.5 mg/kg bd
Administration
IV(ideally centrally) over at least 15 mins(Max rate 1mg/kg/min)
May be diluted if required using sodium chlorde 0.9% ONLY to a maximium concentration of 10mg in 1ml. A filter of 0.22 -0.5micron must be used for diluted IV phenytoin.
Monitoring
Metabolism increases over 5-7 weeks then stabilises, dosage increases will be necessary during this time. Monitor levels
Trough level 40-80 mmols/L or 6-15mg/L
Further Info:
Not compatible with glucose. Flush line with sodium chloride 0.9% before and after administratrion.
Oral dose should only be given 30minutes before or after feeds.
Supply:
Available from pharmacy as a stock item.
|
03.09.01 |
Pholcodine Linctus, BP |
Linctus
for a dry cough |
09.05.02.01 |
Phosphate supplements Phosphate-Sandoz® |
Effervescent tablet
Contains 16.1mmol phosphate, 20.4mmol sodium and 3.1mmol potassium per tablet
|
01.06.04 |
Phosphates (Rectal) Fleet® Ready to use Enema |
Enema |
09.06.06 |
Phytomenadione |
|
09.06.06 |
Phytomenadione Konakion® MM |
|
09.06.06 |
Phytomenadione Konakion® MM Paediatric |
|
11.06 |
Pilocarpine |
Eye drops 1% and 2%
Minims single use 2% |
12.03.05 |
pilocarpine Hydrochloride Salagen® |
|
11.06 |
Pilocarpine preservative free |
|
13.05.03 |
Pimecrolimus Elidel® |
Cream 1% |
06.01.02.03 |
Pioglitazone Actos® |
Tablets 15mg, 30mg, 45mg |
05.01.01.04 |
Piperacillin and Tazobactam |
|
04.02.02 |
Pipotiazine Palmitate Piportil® Depot |
Depot injection |
04.09.03 |
Piracetam Nootropil® |
- Restricted for initiation by or on the advice of a consultant paediatric neurologist
|
10.01.01 |
Piroxicam |
|
10.03.02 |
Piroxicam |
|
05.01.01.05 |
Pivmecillinam Hydrochloride Selexid® |
|
04.07.04.02 |
Pizotifen |
Tablets 0.5mg and 1.5mg |
09.01.07 |
Plerixafor |
|
14.04 |
Pneumococcal polysaccharide conjugate vaccine (adsorbed) Prevenar 13® |
|
14.04 |
Pneumovax® II |
|
13.07 |
Podophyllotoxin Condyline® |
|
13.07 |
Podophyllotoxin Warticon® |
|
06.01.06 |
Polycal® |
Powder
Available for Glucose Tolerance Test. To be given as 113ml Polycal® liquid diluted with water to a total volume of 200-300ml (see BNF).
|
09.02.01.01 |
Polystyrene sulphonate resins Calcium Resonium® |
- 300g tub. Includes a 15g scoop
- For treatment of acute and chronic hyperkalaemia
- Due to be replaced by patiromer sorbitex calcium (Veltassa®)
|
13.09 |
Polytar® |
Discontinued |
11.08.01 |
Polyvinyl Alchohol SnoTears® |
Eye drops |
08.02.04 |
Pomalidomide |
|
08.01.05 |
Ponatinib Iclusig® |
For use in line with NICE TA451 |
03.05.02 |
Poractant Alfa Curosurf® |
Suspension
For specialist use only
Porcine lung extract |
05.02 |
Posaconazole Noxafil® |
|
09.02.01.01 |
Potassium Chloride Kay-Cee-L® |
Syrup
1mL = 1mmol of K+
|
09.02.01.01 |
Potassium Chloride Sando-K® |
Tablet
1 tablet = 12mmol of K+
|
09.02.02.01 |
Potassium Chloride and Glucose Intravenous Infusion |
Available in multiple strengths
Potassium Chloride 10mmol in 500mL with Dextrose 5% (20mmol per litre)
Potassium Chloride 10mmol in 500mL with Dextrose 10% (20mmol per litre)
Potassium Chloride 20mmol in 500mL with Dextrose 5% (40mmol per litre)
Potassium Chloride 20mmol in 500mL with Dextrose 10% (40mmol per litre)
Potassium Chloride 20mmol in 1000mL with Dextrose 5% (20mmol per litre)
Potassium Chloride 40mmol in 500mL with Dextrose 5% (80mmol per litre)
Potassium Chloride 40mmol in 1000mL with Dextrose 5% (40mmol per litre)
|
09.02.02.01 |
Potassium Chloride, Sodium Chloride and Glucose Intravenous Infusion |
Available in multiple strengths
Potassium Chloride 10mmol in 500mL with Dextrose 4% & Sodium Chloride 0.18% (20mmol per litre)
Potassium Chloride 10mmol in 500mL with Dextrose 5% & Sodium Chloride 0.45% (20mmol per litre)
Potassium Chloride 20mmol in 500mL with Dextrose 5% & Sodium Chloride 0.45% (40mmol per litre)
Potassium Chloride 20mmol in 1000mL with Dextrose 2.5% & Sodium Chloride 0.45% (20mmol per litre)
Potassium Chloride 20mmol in 500mL with Dextrose 4% & Sodium Chloride 0.18% (40mmol per litre)
Potassium Chloride 20mmol in 1000mL with Dextrose 4% & Sodium Chloride 0.18% (20mmol per litre)
Potassium Chloride 40mmol in 1000mL with Dextrose 4% & Sodium Chloride 0.18% (40mmol per litre)
|
07.04.03 |
Potassium Citrate |
Oral solution , potassium citrate 30% and citric acid 5%
10ml TDS well diltuted with water for alkalinsation of urine
Sachets also available |
13.11.06 |
Potassium Permanganate Permitabs® |
|
13.11.04 |
Povidone-Iodine Betadine® or Videne® |
|
13.11.04 |
Povidone-Iodine Savlon® Dry Antiseptic |
|
04.09.01 |
Pramipexole |
|
02.09 |
Prasugrel |
Tablet (position statement from cardiology to add) |
02.12 |
Pravastatin |
Tablet
If needed tablets can be crushed and dispersed in water |
02.05.04 |
Prazosin |
|
01.05.02 |
Prednisolone |
|
01.05.02 |
Prednisolone |
|
06.03.02 |
Prednisolone |
Tablets 1mg, 2.5mg, 5mg, 25mg and soluble Tablets 5mg
EC tablets 6x the price of plain tablets without any substantial evidence that they confer any GI benefits
Soluble tablets 15x more expensive than normal tablets
|
08.02.02 |
Prednisolone |
|
11.04.01 |
Prednisolone |
Eye drops
0.5% Predsol® (eye and ear drops); Minims® Prednisolone Sodium Phosphate(Bausch & Lomb)
1% Pred Forte® |
12.01.01 |
Prednisolone 0.5% with Neomycin 0.5% Predsol-N® |
Discontinued in the UK |
11.04.01 |
Prednisolone 0.5% with Neomycin 0.5% Predsol-N® |
|
12.01.01 |
Prednisolone ear drops Predsol® |
Drops 0.5% |
11.04.01 |
Prednisolone preservative free eye drops |
|
04.02.03 |
Pregabalin |
Capsules 25mg, 75mg, 150mg, 225mg and 300mg
For generalised anxiety disorder
Usual dose range 150-600mg daily in two to three divided doses
max daily dose 600mg
max single dose 300mg
|
04.07.03 |
Pregabalin |
Capsule
Should only be considered after both amitriptyline and gabapentin have failed at optimised doses.
If needed capsules can be opened and contents dispersed in water.
|
04.08.01 |
Pregabalin |
|
15.02 |
Prilocaine Hydrochloride Citanest® |
|
04.08.01 |
Primidone Mysoline® |
|
10.01.04 |
Probenecid |
|
24.01 |
Probiotic Infloran® |
Indication:
Prevention of necrotizing enterocolitis (NEC)
Dose:
1/2 capsule ONCE a day with feeds
Administration:
Add Infloran to 2ml milk or water (1 capsule) (EBM / donor or formula) prior to feeds.
Administer half the volume.
If administered mixed with water, give additional to feeds.
Further Info:
As soon as a baby has commenced enteral feeds, and is thought to be tolerating 0.5mls/h of milk.
Probiotics can be stopped once the baby is 34 weeks corrected gestation providing the baby has been tolerating enteral feeds for the 2 weeks prior to this date
Supply:
Available on NNU as a stock item.
Stored in Fridge
|
08.01.05 |
Procarbazine |
|
04.02.01 |
Prochlorperazine |
|
04.06 |
Prochlorperazine |
Tablet
Buccal tablet
Injection (IM route only. Not for IV or SC use.)
|
04.06 |
Prochlorperazine Buccastem® (Bucal preparation) |
|
01.07.02 |
Proctosedyl |
Ointment and Suppository
Ointment - cinchocaine 0.5% and hydrocortisone 0.5%
Suppositories - cinchocaine 5mg and hydrocortisone 5mg |
04.09.02 |
Procyclidine |
|
13.10.05 |
Proflavine Cream, BPC |
|
06.04.01.02 |
Progesterone Cyclogest® |
pessaries 200mg and 400mg |
06.04.01.02 |
Progesterone Gestone® |
|
04.02.01 |
Promazine Hydrochloride Promazine® |
Tablet 25mg, Oral solution 25 mg/5 mL
First generation antipsychotic
Usual dose range 100-200mg up to four times daily
Max daily dose 800mg
Max single dose 200mg
|
03.04.01 |
Promethazine |
Tablets 10mg, 25mg, Liquid 5mg/5ml, Injection 25mg/ml
Promethazine Teoclate (avomine) preferred in pregnancy rather than Promethazine Hydrochloride |
04.06 |
Promethazine Hydrochloride Phenergan |
Tablets 10mg and 25mg |
04.01.01 |
Promethazine Hydrochloride |
Tablets 10mg, 25mg
Usual dose range: 10-25mg at night
Max daily dose 50mg
Max single dose 50mg |
13.11 |
Prontoderm® Foam |
Skin antisepsis
|
12.02.03 |
Prontoderm® Nasal Gel |
Nasal gel
- For patients who cannot use Naseptin® nasal cream while Bactroban® is unavailable
- MRSA suppression: Three times daily for 5 days
|
02.03.02 |
Propafenone |
Cardiology use only |
11.03.01 |
Propamidine Isetionate Brolene® |
Eye drops 0.1% |
15.01.01 |
Propofol |
|
15.01.01 |
Propofol Diprivan® |
|
02.04 |
Propranolol |
Tablet, Capsule MR, Liquid, (Injection - secondary care only)
If needed MR capsules can be opened and beads mixed with water - do not crush. |
04.07.04.02 |
Propranolol |
Tablets 10mg, 40mg |
06.02.02 |
Propylthiouracil |
Tablets 50mg |
02.08.03 |
Protamine Sulphate |
Injection (secondary care only)
Remember maximum dose is 50mg.
To be given by slow intravenous injection over 10 minutes.
|
11.07 |
Proxymetacaine Hydrochloride Minims® |
Eye drops |
11.07 |
Proxymetacaine Hydrochloride 0.5% with Fluorescein Sodium 0.25% Minims® |
Eye drops |
01.06.07 |
Prucalopride Resolor ® |
Tablet
Restricted to gastroenterology consultant initiation for treatment of chronic, resistant constipation in WOMEN in line with NICE guidance (see below) |
05.01.09 |
Pyrazinamide |
|
10.02.01 |
Pyridostigmine Bromide Mestinon® |
|
09.06.02 |
Pyridoxine Hydrochloride |
|
04.02.01 |
Quetiapine Seroquel® |
Tablets 50mg, 100mg, 150mg, 300mg, 400mg. Modified release (XL) tablets also available, but siginificantly more expensive
Second generation anitpsychotic
Usual dose range 300mg-600mg
max daily dose 800mg plain tablets or 800mg XL
|
06.07.01 |
Quinagolide Norprolac® |
Tablets 75 microgram (white)
Starter pack contains 3 x 25microgram (pink) with 3 x 50microgram (blue) |
05.04.01 |
Quinine |
|
10.02.02 |
Quinine |
|
06.04.01.01 |
Raloxifene Hydrochloride Evista® |
Tablet 60mg |
08.01.03 |
Raltitrexed Tomudex® |
|
02.05.05.01 |
Ramipril |
Capsule, Oral solution
If needed capsules can be opened and the contents mixed with water.
Oral solution, for genuine swallowing difficulties or NG tubes
|
11.08.02 |
Ranibizumab Lucentis® |
Intravitreal injection
|
01.03.01 |
Ranitidine |
Tablet 150mg and 300mg, soluble tablet 150mg and 300mg, Syrup 75mg/5ml, Injection 25mg/ml |
24.01 |
Ranitidine |
IV 500mcg/kg slow bolus qds or IV infusion 125 mcg/kg/hour or oral 2 mg/kg tds
|
02.06.03 |
Ranolazine |
Tablets 375mg and 500mg
following specialist recommendation |
04.09.01 |
Rasagiline Azilect® |
|
10.01.04 |
Rasburicase Fastertec® |
|
04.03.04 |
Reboxetine Edronex® |
Tablets 4mg
Usual dose range 4mg twice daily
Max daily dose 12mg
Max single dose 6mg |
15.01.04.03 |
Remifentanil |
|
06.01.02.03 |
Repaglinide |
Tablets 0.5mg, 1mg and 2mg |
A2.05.02 |
Resource® ThickenUp Clear |
- To be lauched as first line thickener for adult patients November 2018
- Contact the speach and language therapists (SALT) team for futher information and advice
|
04.08.01 |
Retigabine |
|
14.04 |
Revaxis® |
|
05.03.05 |
Ribavirin |
|
05.01.09 |
Rifampicin |
|
05.01.09 |
Rifampicin and Isoniazid Rifinah® 300 |
|
05.01.09 |
Rifampicin and Isoniazid Rifinah® 150 |
|
05.01.09 |
Rifampicin and Isoniazid and Pyrazinamide Rifater® |
|
05.01.09 |
Rifampicin, isoniazid, pyrazinamide and ethambutol Voractiv® |
|
04.09.03 |
Riluzole |
|
11.04.01 |
Rimexolone Vexol® |
Eye drops 1% |
13.05.03 |
Risankizumab Skyrizi |
As per NICE guidelines:
TA596: Risankizumab for treating moderate to severe plaque psoriasis |
06.06.02 |
Risedronate |
|
04.02.01 |
Risperidone Risperdal® |
Tablets,500 micrograms,1 mg, 2 mg, 3 mg, 4 mg, 6 mg
Orodispersible tablets also available
Liquid 1 mg/mL
Note Liquid may be diluted with any non-alcoholic drink, except tea
Second generation antipsychotic
Initially 2mg daily Usual dose range 4-6mg daily
Max daily dose 16mg, no benefit generally seen above 10mg daily
|
04.02.02 |
Risperidone Risperdal Consta® |
|
05.03.01 |
Ritonavir Norvir® |
|
08.02.03 |
Rituximab MabThera® |
|
10.01.03 |
Rituximab (rheumatology) MabThera® |
|
02.08.02 |
Rivaroxaban |
Treatment of DVT or PE:
GPs may initiate in line with local guidance.
Treatment of ACS:
- Specialist initiation only, awaiting local guidance
GPs may continue after specialist initiation. See Primary care guideline and prescribing information sheet
Prophylaxis of VTE post hip and knee replacement surgery:
Complete course will be supplied by hospital, to start upon discharge. Post-op whilst in-patient to be treated with parenteral anticoagulants
If needed tablets can be crushed and dispersed in water. |
04.11 |
Rivastigmine Exelon® |
Tablets 1.5mg and 3mg, Patches 4.6mg/24hours and 9.5mg/24hours
Second Line for Mild to moderate Alzheimers disease
Usual dose range 3-6mg twice daily (oral) and 4.6-9.5mg/24hour patch
Max single dose 12mg (oral) and 9.5mg/24hr patch |
15.01.05 |
Rocuronium Bromide |
|
09.01.04 |
Romiplostim |
Injection
Restriced for use in line with NICE guidelines |
04.09.01 |
Ropinirole |
|
15.02 |
Ropivacaine Hydrochloride Naropin® |
|
11.08.02 |
Rose Bengal Minims® Rose Bengal |
|
02.12 |
Rosuvastatin |
Tablet
Restricted for 3rd line use by consultants and SpRs in hypercholesterolaemia clinic and cardiology
|
14.04 |
Rotavirus vaccine Rotarix® |
|
04.08.01 |
Rufinamide Inovelon® |
Tablets
specialist use only |
08.01.05 |
Ruxolitinib Jakavi® |
|
03.01.01.01 |
Salbutamol |
Short acting beta agonist
The following formulations are available on formulary: MDI, breath actuated MDI, DPI, nebules, tablets, MR capsules, injection
1st line = MDI + spacer
2nd line = CFC free breath actuated (Salamol Easi-Breathe - prescribe by brand)
3rd line = DPI (Easyhaler® Salbutamol)
Nebules also available. Nebs may be diluted with 0.9% sodium chloride if needed
|
03.01.01.01 |
Salbutamol Ventmax® SR |
|
13.05.02 |
Salicyclic acid 2% and zinc 24% paste |
|
13.07 |
Salicylic Acid 16.7% with Lactic Acid 16.7% Salactol® |
|
13.05.02 |
Salicylic Acid in White Soft Paraffin |
|
03.01.01.01 |
Salmeterol |
Long acting beta-agonist
Evohaler (25mcg/dose) and Accuhaler (50mcg/dose) available
|
05.03.01 |
Saquinavir Invirase® |
|
01.07.02 |
Scheriproct® |
Suppositories and ointment
Contains Cinchocaine 0.5% and prednisolone 0.19% |
10.01.03 |
Secukinumab Cosentyx® |
For use in line with NICE guidance for treatment of:
Psoriatic arthritis
Ankylosing spondylitis
For use in plaque psoriasis, see section 13.5.3 |
13.05.03 |
Secukinumab Cosentyx® |
For use in line with NICE guidance:
TA350: Secukinumab for treating moderate to severe plaque psoriasis
TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
04.09.01 |
Selegiline Hydrochloride |
|
09.05.05 |
Selenium Selenase® |
IV injection
TPN team |
06.01.02.03 |
Semaglutide Ozempic® |
- First choice glucagon-like peptide-1 receptor agonist in parimary care
|
01.06.02 |
Senna |
Tablet 7.5mg, Syrup 7.5mg/5ml |
04.03.03 |
Sertraline |
Tablets 50mg, 100mg
Usual dose range 50-200mg daily
Max daily dose 200mg
Max single dose 200mg |
09.05.02.02 |
Sevelamer Carbonate Renvela® |
Powder for oral suspension (sachets)
|
09.05.02.02 |
Sevelamer Hydrochloride Renagel® |
Tablets
|
15.01.02 |
Sevoflurane |
|
13.09 |
Shampoos Ceanel Concentrate® |
|
02.05.01 |
Sildenafil |
Tablet
Secondary care only for pulmonary arterial hypertension (PAH) Revatio 20mg not stocked only keep sildenafil 25mg tablets.
NOT for erectile dysfunction (ED)
|
07.04.05 |
Sildenafil |
|
13.07 |
Silver Nitrate AVOCA® |
caustic pencil, tip containing silver nitrate 40%, potassoim nitrate 60% |
13.10.01.01 |
Silver Sulfadiazine Flamazine® |
Cream |
05.03.03.02 |
Simeprevir Olysio |
First line for Genotype I and IV, in accordance with NHS England policy and NICE |
01.01.01 |
Simeticone Infacol® |
For paediatrics and gastroenterology use |
03.09.02 |
Simple Linctus, BP |
Linctus
Considered to be of limited clinical value. May be prescribed if appropriate in secondary care
|
03.09.02 |
Simple Linctus, Paediatric BP |
|
02.12 |
Simvastatin |
Tablets
If needed tablets can be crushed and dispersed in water. Poorly soluble and degrades rapidly so crush thoroughly and give immediately |
08.02.02 |
Sirolimus Rapamune® |
|
06.01.02.03 |
Sitagliptin Januvia® |
Tablets 25mg, 50mg and 100mg |
09.08.01 |
Sodium Benzoate |
|
09.02.01.03 |
Sodium Bicarbonate |
Capsule (500mg = approx. 6 mmol each of Na+ and HCO3-)
Capsules can be opened and the contents dispersed in water.
|
09.02.02.01 |
Sodium Bicarbonate |
Available in multiple strengths:
Sodium Bicarbonate 1.26% 500ml polyfusor (supply problems - probably not available)
Sodium Bicarbonate 1.4% 500ml polyfusor (supply problems - probably not available)
Sodium Bicarbonate 4.2% 10ml ampoules or 500ml polyfusor
Sodium Bicarbonate 8.4% 10ml ampoules or 500ml polyfusor
|
12.01.03 |
Sodium Bicarbonate |
Ear drops |
24.01 |
Sodium Bicarbonate |
2-3 mmol/kg by slow infusion 8.4%sodium bicarbonate = 1mmol/ml Dilute with water Monitor infusion site closely, extravasation can cause severe tiisue damage
|
18 |
Sodium calcium edetate |
|
09.02.01.02 |
Sodium Chloride Slow Sodium® |
|
11.08.01 |
Sodium Chloride |
|
11.08.01 |
Sodium Chloride Minims® Saline |
Eye drops 0.9% (preservative free)
|
13.11.01 |
Sodium Chloride 0.9% |
|
11.08.01 |
Sodium Chloride 0.9% Solutions |
|
09.02.02.01 |
Sodium Chloride Intravenous |
Available in multiple strengths.
Infusions:
Sodium Chloride 0.45% infusion 500ml bag or polyfusor
odium Chloride 0.9% infusion 50ml, 100ml, 250ml, 500ml, 1 litre
Sodium Chloride 1.8% infusion 500ml
Sodium Chloride 2.7% infusion 500ml polyfusor
Ampoules:
Sodium Chloride 0.9% injection 2ml, 5ml, 10ml and 20ml ampoules
Sodium Chloride 30% injection 10ml
|
07.04.03 |
Sodium Citrate |
|
07.04.04 |
Sodium Citrate |
|
06.06.02 |
Sodium Clodronate |
Tablet 800mg
|
11.04.02 |
Sodium Cromoglicate |
Eye drops 2% |
09.01.01.01 |
Sodium Feredetate Sytron® |
Elixir
Sodium feredetate 190 mg equivalent to 27.5 mg of iron/5 mL
|
11.08.01 |
Sodium Hyaluronate Hylo-Forte® |
|
11.08.01 |
Sodium Hyaluronate Hylo-Tear® |
Eye drops |
11.99.99.99 |
Sodium Hyaluronate |
|
18 |
Sodium nitrite 3% Injection |
|
02.05.01 |
Sodium Nitroprusside |
Injection (secondary care only) |
09.08.01 |
Sodium Phenybutyrate Ammonaps®, Pheburane® |
|
24.01 |
Sodium Phosphate |
0.5mmol (=1.6ml) bd. Prescribe as mmol stop at discharge
|
01.06.02 |
Sodium Picosulfate |
Elixir 5mg/5ml, capsules (perles) 2.5mg |
01.06.05 |
Sodium picosulphate with magnesium citrate Picolax®, CitraFleet® |
Sachet |
02.13 |
Sodium Tetradecyl Sulphate |
Injection (secondary care only)
|
18 |
Sodium thiosulphate |
|
04.02.03 |
Sodium valproate |
Tablets 100mg (crushable), 200mg, 500mg, 200mg chrono, 300mg chrono, 500mg chrono
Bipolar Affective Disorder
usual dose range 500mg-1000mg in divided doses
max daily dose 2000mg |
04.08.01 |
Sodium Valproate Epilim® |
|
04.08.01 |
Sodium Valproate Epilim® Intravenous |
|
04.08.01 |
Sodium Valproate |
Epilim®, Epilim Chrono®, Epilim® injection
|
04.08.01 |
Sodium Valproate Epilim® Chrono |
|
10.01.03 |
Soldium Aurothomalate Myocrisin® |
|
07.04.02 |
Solifenacin Vesicare® |
Tablet 5mg and 10mg |
06.05.01 |
Somatropin Saizen® |
Injection |
02.04 |
Sotalol |
Tablet
Management of arrythmias.
If needed tablets can be crushed and dispersed in water.
|
02.02.03 |
Spironolactone |
Tablet 25mg, 50mg, 100mg, Oral Suspension 10mg/5ml
Potasium sparing diuretic |
24.01 |
Spironolactone |
1 mg/kg bd initially Oral Potassium canreonate (Soldactone or Aldactone) 1-1.5mg/kg/dose (usually bd) can be given IV. Soldactone dilution: 200mg vial, add 2 ml H20; then take 1 ml of this ’Soldactone’ solution and add 9 mls 0.9% NaCl; this solution has 10mg ’Soldactone in 1 ml. Give the appropriate dose as slow bolus over 3 minutes. Potassium canreonate also comes as ’Aldactone’. Vial is 200mg in 10 mls. to make up, take 1 ml (=20mg) of solution and dilute to 20mls with 0.9% NaCl. This solution is 1mg/ml. Give the appropriate dose as slow bolus over 3 minutes.
|
07.03.03 |
Spremicidal Contraceptives Gygel® |
|
03.01.05 |
Standard range peak flow meter Mini-Wright® |
Suitable for adults and children
60-800 litres/minute
low range also available for adults and children with severely restricted airflow 30-400 litres/minte |
05.03.01 |
Stavudine Zerit® |
|
02.10.02 |
Streptokinase |
Injection (secondary care only)
|
05.01.09 |
Streptomycin Sulphate |
|
01.03.03 |
Sucralfate Antepsin® |
Tablet 1 gram, Suspension 1gram/5ml
Interacts with enteral feeds and may block NG tubes
March 2014 Current supply issues however limited stock available direct from manufacturer - pharmacy to order direct supplies
|
24.01 |
Sucrose 66% |
Working weight <750g - 0.05ml (31.25mg) max tds 750g-999g - 0.1ml (62.5mg) max tds 1000g - 1499g -0.2mls (125mg) >1500g - 0.4mls (250mg)
|
01.05.01 |
Sulfasalazine |
Tablets 500mg E/C and non E/C |
10.01.03 |
Sulfasalazine |
|
10.01.04 |
Sulfinpyrazone |
|
04.02.01 |
Sulpiride |
Tablet 200mg, 400mg and Liquid 200mg/5ml |
04.07.04.01 |
Sumatriptan |
Tablets 50mg, 100mg |
08.01.05 |
Sunitinib Sutent® |
For use in line with NICE TA169, TA178, TA179 & TA449 |
15.01.05 |
Suxamethonium Chloride |
|
24.01 |
Sytron Sodium Feredetate |
0.5 mls tds from 1 month if not on mostly formula feeds |
13.05.02 |
Tacalcitol Curatoderm® |
|
02.11 |
TachoSil Fibrinogen and thrombin |
Fibrinogen and thrombin dried on to a collagen matrix Restricted to use by urology for use in robotic assisted laparoscopic, laparoscopic and open major urological surgery. Conditions include renal, prostate and bladder cancer
Approved at DTC 12/07/2017 for 6 months use to assess whether superior to Surgicel |
08.02.02 |
Tacrolimus Adoport®, Prograf® |
|
13.05.03 |
Tacrolimus Protopic® |
Ointment 0.03%, Ointment 0.1%
|
08.02.02 |
Tacrolimus MR Advagraf® |
|
08.03.04.01 |
Tamoxifen |
|
07.04.01 |
Tamsulosin |
Capsule m/r 400 microgram |
04.07.02 |
Tapentadol Palexia® |
Standard release 50mg (tablets)
Modified release: Palexia SR 50mg, 100mg, 150mg, 200mg, 250mg
Specialist initiation - for chronic pain in patients either unresponsive or unable to tolerate morphine, fentanyl, oxycodone and buprenorphine (i.e. fifth line strong opioid). Tapentadol can be used 3rd line only if the patient has not responded to morphine and buprenorphine and was showing symptoms of neuropathic pain.
|
05.01.07 |
Teicoplanin Targocid® |
|
04.01.01 |
Temazepam |
Tablet 10mg and 20mg, Oral solution 10mg/5ml
Second choice for insomnia
Usual dose range: 10-20mg at night
Max daily dose 20mg
Max single dose 20mg
CD storage requirements apply within BTHFT for ALL temazepam products
|
15.01.04.01 |
Temazepam |
|
08.01.05 |
Temozolomide Temodal® |
|
02.10.02 |
Tenecteplase |
Injection (secondary care only)
|
05.03.01 |
Tenofovir and Emtricitabine Truvada® |
|
05.03.01 |
Tenofovir Disproxil Viread® |
|
05.02 |
Terbinafine |
|
13.10.02 |
Terbinafine |
1% cream |
03.01.01.01 |
Terbutaline |
Short-acting beta-agonist
Turbohaler (500mcg/dose) and Respules (2.5mg/ml) available
Limited use where patient intolerant of salbutamol and in those patients whose condition is exacerbated by an aerosol
|
06.06.01 |
Teriparatide Forsteo® |
injection 250micrograms/ml |
06.05.02 |
Terlipressin |
|
06.04.02 |
Testosterone and Esters Nebido® |
Injection |
06.04.02 |
Testosterone gel Tostran® |
Gel 2% (10 mg/metered application), |
06.04.02 |
Testosterone injection Sustanon 250® |
Injection |
14.05.02 |
Tetanus immunoglobulin |
|
04.09.03 |
Tetrabenazine Xenazine® 25 |
|
15.02 |
Tetracaine (Amethocaine) |
|
24.01 |
Tetracaine 4% AMETOP® |
Indication:
Local Anaestetic - Lumber Puncture(NeoClear)
Dose:
Apply contents of tube (or appropriate proportion)
Administration:
Apply to site of lumber puncture and cover with occlusive dressing; remove gel and dressing after 30 to 45 minutes for lumber puncture.
Monitoring:
Local skin reactions
Storage & Supply:
Available on NNU as a stock item. Stored in Fridge |
11.07 |
Tetracaine Hydrochloride (Amethocaine Hydrochloride) Minims® |
Eye drops |
06.05.01 |
Tetracosactide Synacthen® |
Injection 250micrograms/ml
Short Synacthen test (30 min) 250 micrograms as a single dose
Depot injection 1mg/ml |
20 |
TETRAHYDROBIOPTERIN Tablets 10 mg |
|
08.02.04 |
Thalidomide Pharmion® |
|
03.01.03 |
Theophylline Nuelin® SA |
Tablets m/r 250mg
Prescribe by brand
175mg tablets not stocked at BTHFT |
03.01.03 |
Theophylline Slo-Phyllin® |
Capsules m/r 60mg, 125mg and 250mg
prescribe by brand
If necessary Contents of the capsule (enteric-coated granules) may be sprinkled on to a spoonful of soft food (e.g. yoghurt) and swallowed without chewing
|
03.01.03 |
Theophylline Uniphyllin® Continus |
Tablets m/r 200mg, 300mg and 400mg
Prescribe by brand
May be appropriate to give larger evening or morning dose to achieve optimum therapeutic effect when symptoms most severe in patients whose night or daytime sysmptoms persist despite other therapy, who are not currently recieving theophylline, total daily requirement may be added as single evening or morning dose
|
09.06.02 |
Thiamine Pabrinex® |
I/M High Potency injection, for intramuscular use only, ascorbic acid 500 mg, nicotinamide 160 mg, pyridoxine hydrochloride 50 mg, riboflavin 4 mg, thiamine hydrochloride 250 mg/7 mL. (in 2 amps)
Excipients include benzyl alcohol (avoid in neonates)
I/V High Potency injection, for intravenous use only, ascorbic acid 500 mg, anhydrous glucose 1 g, nicotinamide 160 mg, pyridoxine hydrochloride 50 mg, riboflavin 4 mg, thiamine hydrochloride 250 mg/10 mL. (in 2 × 5 mL amps)
Wernickes Encephalopathy
2-3 pairs of ampoules three times a day for 2 to 4 days depending on response
Prophylaxis of Wernickes Encephalopathy
One pair of ampoules twice daily for at least 3 to 5 days |
09.06.02 |
Thiamine |
Tablets 50mg and 100mg
Usual dose range: 50 to 100mg TDS |
15.01.01 |
Thiopental |
|
06.04.01.01 |
Tibolone Livial® |
Tablet 2.5mg |
02.09 |
Ticagrelor |
Position statement from cardiology to add |
05.01.03 |
Tigecycline Tygacil® |
|
13.05.03 |
Tildrakizumab Ilumetri |
To be prescribed as per NICE guidelines:
TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
11.06 |
Timolol |
Eye drops 0.25% and 0.5% |
05.04.02 |
Tinidazole |
|
02.08.01 |
Tinzaparin Innohep® |
- 10,000 units/ml syringe for subcutaneous injection
- 20,000 units/ml syringe for subcutaneous injection
- 20,000 units/ml 2ml vial
- For prophylaxis and treatment of VTE
|
08.01.03 |
Tioguanine Lanvis® |
|
03.01.02 |
Tiotropium Spiriva® |
Inhalation powder 18microgram/dose, capsules for use with Handihaler
Respimat device no longer recommended for prescribing |
02.09 |
Tirofiban |
|
05.01.04 |
Tobramycin |
|
10.01.03 |
Tocilizumab RoActemra® |
|
01.05.03 |
Tofacitinib Xeljanz |
To be used as per NICE guidelines:
TA547: Tofacitinib for moderately to severely active ulcerative colitis
Available as oral tablets |
10.01.03 |
Tofacitinib Xelijang® |
Restricted for treatment of rheumatoid arthritis through patient access scheme
NICE TA currently in development. Due Jan 2018 |
13.05.03 |
Tofacitinib Xeljanz |
Oral tablets.
As per NICE guidelines for psoriatic arthritis:
TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
24.01 |
Tolazoline |
1 mg/kg IV over 10 mins then 0.2-2 mg/kg/hr Stock 25 mg/ml Weight x 50 mg tolazoline diluted to 50 mls in 5% dextrose 1ml/hr = 1mg/kg/hr
|
07.04.02 |
Tolterodine |
Tablets 1mg, 2mg
Capsules modified release 4mg |
13.03 |
Topical local anaesthetics |
Lidocaine 5% ointment |
04.07.04.02 |
Topiramate |
|
04.08.01 |
Topiramate |
|
08.01.05 |
Topotecan Hycamtin® |
|
06.01.01.02 |
Toujeo® Insulin glargine |
Long acting recombinant human insulin analogue
300 units/ml pre-filled Solostar pen (1.5ml/pen)
NOT bioequivalent to insulin glargine 100 units/ml - not directly interchangeable (see SPC)
Restricted for initiation by diabetes team |
04.07.02 |
Tramadol
| Soluble tablet, Capsule, Slow release tablet, Injection
|
02.11 |
Tranexamic Acid |
Tablet, Injection
Topical solution (unlicensed). In an emergency 500mg/5ml injection can be used topically.
If needed tablets can be crushed and dispersed in water. |
12.03.04 |
Tranexamic Acid Mouthwash |
|
08.01.05 |
Trastuzumab Herceptin® |
|
11.06 |
Travoprost Travatan® |
Eye drops 40micrograms/ml |
11.06 |
Travoprost with Timolol DuoTrav® |
eye drops, travoprost 40micrograms and timolol 5mg/ml |
04.03.01 |
Trazodone |
Capsules and Tablets 50mg, 100mg and 150mg
Liquid 50mg/5ml
Usual dose range 100-300mg daily
Max daily dose 600mg
Max single dose 300mg |
08.01.01 |
Treosulfan |
|
06.01.01.02 |
Tresiba® Insulin Degludec |
Long acting recombinant human insulin analogue
100units/ml Penfill® cartridges for Novo Nordisk® devices
100units/ml FlexTouch® prefilled pen
200units/ml FlexTouch® prefilled pen
Counter shows number of units regardless of strength
Restricted to initiation by diabetes team |
08.01.05 |
Tretinoin Vesanoid® |
|
06.03.02 |
Triamcinolone Kenalog® |
Intra-articular/intramuscular injection 40mg/ml |
10.01.02.02 |
Triamcinolone Acetonide Adcortyl® |
Injection 10mg in 1mL
|
10.01.02.02 |
Triamcinolone Acetonide Kenalog® |
Injection: 40mg in 1mL
Vial
Pre filled syringe
|
12.02.01 |
Triamcinolone Acetonide Nasacort® |
Nasal spray 55micrograms per spray
|
09.08.01 |
Trientine Dihydrochloride |
|
04.02.01 |
Trifluoperazine |
Tablet 1mg, 5mg, Oral solution 1mg/5ml and 5mg/5ml
First generation antipsychotic
Usual dose range: 2.5mg twice daily initially
Max daily dose: 50mg
Max single dose: 25mg |
04.06 |
Trifluoperazine |
|
04.09.02 |
Trihexyphenidyl |
|
05.01.08 |
Trimethoprim |
|
05.01.13 |
Trimethoprim |
|
24.01 |
Trimethoprim |
Treatment mature babies 4 mg/kg bd oral Prophylaxis 2 mg/kg at night |
04.03.01 |
Trimipramine Surmontil® |
|
01.03.03 |
Tripotassium Dicitratobismuthate De-Noltab® |
Tablets 120mg
An addition for second or third line H. pylori eradiction therapy
|
06.07.02 |
Triptorelin |
Decapeptyl®SR, Gonapeptyl Depot® |
08.03.04.02 |
Triptorelin Gonapeptyl Depot® |
|
08.03.04.02 |
Triptorelin- Decapeptyl® SR |
|
24.01 |
Trometamol THAM |
Try 1.5mmol/kg (5ml) infused over 30mins and then reassess Usual stock is 0.3 Molar =0.3mmol/ml Watch for respiratory depression
|
20 |
TROMETAMOL (THAM) 125ML Injection 3.6% (0.3M) |
|
11.05 |
Tropicamide |
Mydriacyl® 0.5% and 1% eye drops
Minims® Tropicamide 0.5% and 1% single use eye drops |
07.04.02 |
Trospium |
Tablet 20mg
Capsule Modified release 60mg |
04.03.04 |
Tryptophan |
Tablets 500mg
Adjunct for Adult Depression
Usual dose range 3-6grams daily in three divided doses
Max daily dose 6grams
|
07.03.05 |
Ulipristal EllaOne® |
Tablet 30mg, single dose
effective if taken within 120 hours (5days) of unprotected intercourse
|
06.04.01.02 |
Ulipristal acetate |
|
03.01.02 |
Umeclidinium Incruse Ellipta® |
|
03.01.04 |
Umeclidinium, vilanterol Anoro Ellipta® |
Dry powder inhaler Umeclidinium 55 micrograms/vilanterol 22 micrograms
|
13.02.01 |
Unguentum M® |
Cream |
10.01.03 |
Upadacitinib Rinvoq |
Upadacitinib is avaiable as 15mg prolonged release tablets.
Upadacitinib can be prescribed as per NICE guidelines:
|
06.05.01 |
Urofollitropin |
|
01.09.01 |
Ursodeoxycholic acid Ursofalk® |
Tablet, Capsule, Suspension
|
24.01 |
Ursodeoxycholic Acid |
10mg/kg twice daily |
01.05.03 |
Ustekinumab Stelara® |
To be prescribed as per guidelines:
TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
In the treatment regimen, the first dose of Stelara is administered intravenously. The first subcutaneous administration of Stelara should take place at week 8 after the intravenous dose. |
10.01.03 |
Ustekinumab |
|
13.05.03 |
Ustekinumab Stelara |
As per NICE guidelines:
TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
TA340: Ustekinumab for treating active psoriatic arthritis
TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
05.03.02.01 |
Valaciclovir Valtrex® |
|
05.03.02.02 |
Valganciclovir Valcyte® |
|
02.05.05.02 |
Valsartan, sacubitril Entresto® |
Film coated tablets
Valsartan 26mg/sacubitril 24mg Valsartan 51mg/sacubitril 49mg Valsartan 103mg/sacubitril 97mg
According to NICE TA388 for treating symptomatic chronic heart failure with reduced ejection fraction |
05.01.07 |
Vancomycin |
|
24.01 |
Vancomycin |
15 mg/kg/dose bd infused over 1 hour Start every 24 hours if <28 weeks. Use 12 hourly if postmenstrual age >28/40 and 8 hourly if postmenstrual age >35/40. Use with caution if renal impairment 500mg vial dissolved in 4.8 mls water NEEDS FURTHER DILUTION TO 5 mg/ml by mixing 1ml of this concentrated solution with 19mls 5% dextrose. Levels: pre-dose(trough) 10-15 mcg/ml
|
04.10.02 |
Varenicline Champix® |
|
15.01.05 |
Vecuronium Bromide |
|
01.05.03 |
Vedolizumab Entyvio® |
Vedolizumab is now available as an IV infusion and SC injection. For more information about dosing, contact the pharmacy or gastroenterology teams.
To be used as per NICE guidelines:
TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
TA352: Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy |
04.03.04 |
Venlafaxine |
Tablets and capsules 37.5mg, 75mg, 150mg.
Usual dose range 37.5-75mg twice daily
Max daily dose 375mg |
04.03.04 |
Venlafaxine Efexor® XL |
Tablets and Capsules, MODIFIED RELEASE 75mg, 150mg
Usual dose range 75-225mg once daily
Max daily dose 225mg
Max single dose 225mg |
02.06.02 |
Verapamil |
Tablet, MR tablet, injection (secondary care only)
If needed tablets can be crushed and dispersed in water. Do not crush MR formulations. |
11.08.02 |
VibeX Rapid® Riboflavin 0.1% |
1.5ml pre-filled syringe Restricted to use by opthalmic surgeons for ‘epithelium-off’ photochemical corneal collagen cross-linkage (epithelium-off CXL) to treat progressive keratoconus or keratectasia after laser refractive surgery.
|
04.08.01 |
Vigabatrin Sabril® |
|
08.01.04 |
Vinblastine Sulphate |
|
08.01.04 |
Vinblastine Sulphate Velbe® |
|
08.01.04 |
Vincristine Sulphate Oncovin® |
|
08.01.04 |
Vincristine Sulphate |
|
08.01.04 |
Vindesine Sulphate Eldisine® |
|
08.01.04 |
Vinorelbine |
|
08.01.04 |
Vinorelbine Navelbine® |
|
09.06.07 |
Vitamin and mineral supplements Forceval Soluble® |
|
09.06.07 |
Vitamin and mineral supplements Ketovite® |
|
09.06.07 |
Vitamin and mineral supplements Forceval® |
|
09.06.02 |
Vitamin B Tablets, Compound Strong |
Tablets
Usual dose : 2 three times daily
|
24.01 |
Vitamin E Tocopheryl Acetate |
50mg once daily O/NG (not a /kg dose) 50mg=75units |
24.01 |
Vitamin K Phytomendione |
1mg once daily O/NG (not a /kg dose) Base Line clotting required and regularly monitor |
09.06.01 |
Vitamins A and D |
|
09.06.01 |
Vitamins A C and D Healthy Start Children's Vitamin Drops® |
|
11.08.01 |
VitA-POS |
Eye ointment
Retinol palmitate 250 units/g, white soft paraffin, light liquid paraffin, liquid paraffin, wool fat
|
05.02 |
Voriconazole Vfend® |
|
11.03.02 |
Voriconazole |
- Intravitreal injection
- For use by opthalmologists only
|
02.08.02 |
Warfarin |
Tablets 0.5mg (white) 1mg (brown), 3mg (blue,) 5mg (pink),
Suspension 1mg/ml (licensed) - £99 per 150ml
If needed tablets can be crushed and dispersed in water.
|
12.02.02 |
Xylometazoline Otrivine® |
spray, for inpatient use, do not use for more than 7 days |
01.07.02 |
Xyloproct® |
Ointment
contains lidocaine 5% and hydrocortisone 0.275% |
03.03.02 |
Zafirlukast Accolate® |
Tablet 20mg |
13.02.02 |
Zinc and Caster Oil Ointment BP |
Ointment |
09.05.04 |
Zinc Sulphate |
Effervescent Tablet
45mg elemental zinc |
06.06.02 |
Zoledronic Acid |
IV infusion 4mg/5ml (Zometa)
for reduction of bone damage in advanced malignancies involving bone
IV infusion 5mg/100ml (50micrograms/ml)
Treatment of osteoporosis- Once yearly dose
|
04.01.01 |
Zolpidem |
Tablets 5mg, 10mg
Usual dose range: 5-10mg at night
Max daily dose 10mg
Max single dose 10mg |
04.08.01 |
Zonisamide Zonegran® |
|
04.01.01 |
Zopiclone |
Tablets 3.75mg, 7.5mg
Usual dose range: 3.75-7.5mg at night
Max daily dose 7.5mg
Max single dose 7.5mg |
04.02.01 |
Zuclopenthixol Clopixol® |
Tablet 2mg. 10mg and 25mg
First generation antipsychotic
Usual dose range: 20-50mg in divided doses
Max daily dose: 150mg
Max single dose: 50mg
|
04.02.01 |
Zuclopenthixol Acetate Clopixol Acuphase® |
Deep IM injection 200mg/ml snd 500mg/ml
Max 600mg weekly |
04.02.02 |
Zuclopenthixol Decanoate Clopixol® |
Depot Injection |